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The implantable cardioverter deﬁbrillator (ICD) has
emerged as an important treatment option for selected
patients who are at risk of sudden cardiac death.
Randomized trials have consistently shown that ICD
implantation reduces mortality in patients with heart
failure and reduced left ventricular function, as well as in
patients who have suffered a cardiac arrest (1–3). Rec-
ommendations on the use of the ICD in clinical practicehave been provided in four important guideline docu-
ments sponsored by the American College of Cardiology
(ACC), the American Heart Association (AHA), Heart
Rhythm Society (HRS), and the European Society of Car-
diology (ESC) (4–7). For each indication for ICD therapy,
both a Class of indication (I, II, or III) and level of evidence
for the indication (A, B, or C) are provided. To ensure that
recommendations are evidence-based, Class I recom-
mendations are typically based on the results of pro-
spective randomized clinical trials. For example, in the
ACC/AHA/HRS 2012 Focused Update of the ACC/AHA/HRS
2008 Guidelines on Device-Based Therapy, no new rec-
ommendations on the indications for ICD therapy were
made, with the important exception of ICDs that also
provide cardiac resynchronization therapy (CRT-D) (8).
The lack of new recommendations reﬂects the fact that
clinical trials over this period of time have focused on
studying the effectiveness of ICDs that provide CRT
therapy and not on the outcomes of non-CRT deﬁb-
rillators. Randomized clinical trials study the effects of a
particular treatment on a carefully selected and relatively
homogeneous group of patients who meet speciﬁc inclu-
sion and exclusion criteria for a particular clinical trial.
Consistent with this approach, the indications for ICD
therapy developed in the various guideline statements
are limited to the speciﬁc populations of patients who
participated in these clinical trials. Although the resulting
guidelines are of great value, clinicians are often asked to
make decisions regarding ICD therapy in patient pop-
ulations who were not included or who were poorly rep-
resented in prior clinical trials. For these patients, there
are no speciﬁc indications for ICD therapy. The purpose of
this consensus statement is to provide clinicians with
guidance on the use of ICD therapy in the management of
some common populations of patients who are not repre-
sented in clinical trials and who therefore are not speciﬁ-
cally included in the various guidelines that provide
indications for ICD therapy. However, recommendations
made in this document cannot account for all the nuances
of clinical medicine and cannot replace careful clinical
judgment for the care of an individual patient.
This document is not meant to be a comprehensive
guideline on a speciﬁc clinical subject. Recommendations
are not given a Class recommendation; instead, phrases
such as “is recommended,” “can be useful,” “can be con-
sidered,” and “is not recommended” are used. In addition,
no levels of evidence are provided because there are no
randomized controlled trials that have been speciﬁcally
designed to address the clinical conditions posed by this
document. The recommendations are largely based on
subgroup analysis of randomized clinical trials, retro-
spective studies, analyses of large registries, and expert
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methodology as an Appropriate Use Criteria document (9).
For this consensus document, the writing group eval-
uated the available data on four important situations for
which ICD therapy might be beneﬁcial in selected pop-
ulations that were not consistently included in random-
ized clinical trials: 1) use of an ICD in patients with an
abnormal troponin that is not due to a myocardial
infarction (MI), 2) use of an ICD within 40 days after a
myocardial infarction, 3) use of an ICD within the ﬁrst
90 days after revascularization, and 4) use of an ICD in the
ﬁrst 9 months after initial diagnosis of nonischemic car-
diomyopathy. In addition, the writing group evaluated
the utility of an atrial lead in a patient requiring ICD
therapy without cardiac resynchronization therapy. The
members of the writing group performed a compre-
hensive literature search, and then developed a series of
recommendations with an explanation of the reasoning
and research used to make each recommendation. Initial
recommendations and alternatives were discussed and
edited by the entire group. Final recommendations were
sent to the entire group for anonymous voting. All rec-
ommendations presented in this document were agreed
upon by at least 80% of the members of the writing group.
The writing group members were selected by the follow-
ing societies: Heart Rhythm Society, American College of
Cardiology, American Heart Association, Heart Failure
Society of America, and the Society of Thoracic Surgeons.
Members of the writing group are from the United States,
Canada, and Europe, and were selected as leaders in their
ﬁelds with the majority of the writing group having no
signiﬁcant relationships with the medical device industry.
All members of the writing committee were allowed to
vote unless a signiﬁcant relationship with industry was
identiﬁed by the individual or the co-chairs.
2. CURRENT GUIDELINES THAT ADDRESS ICD USE
Several Guidelines have been published that evaluate the
use of ICDs in various clinical situations (Table 1) (4–7).
Although generally similar, there are some differences
among the various documents because each group eval-
uated ICD implantation from a slightly different per-
spective. For example, three of the guidelines, the ACC/
AHA/ESC 2006 Guidelines for Management of Patients
with Ventricular Arrhythmias and the Prevention of
Sudden Cardiac Death, the ACC/AHA/HRS 2008 Guide-
lines on Device-Based Therapy, and the 2009 ACC/AHA
Focused Update of the 2005 Heart Failure Guidelines,
addressed the use of non-CRT ICD therapy in patients
with heart failure (4–6). The 2008 Guidelines on Device-
Based Therapy and the 2009 Focused Update of the 2005
Heart Failure Guidelines provide speciﬁc ejection fraction
cut-offs that parallel the values used in randomizedclinical trials (4,5). In the text discussing the basis for the
recommendations, the 2008 Guidelines on Device-Based
Therapies noted that ejection fraction determination could
be variable and suggested that clinicians rely on the most
clinically accurate modality at their speciﬁc institution (5).
Using a slightly different approach, the 2006 Guidelines
on Ventricular Arrhythmias acknowledged the variability
of many measures for ejection fraction and provided a
range in the actual recommendations that provides
increased ﬂexibility at the cost of potential overuse (7).
Clearly, the trend has been an emphasis on the incorpo-
ration of results from randomized clinical trials into the
recommendations made by Guidelines documents.
3. RANDOMIZED CONTROLLED TRIALS OF
ICD THERAPY FOR PRIMARY PREVENTION OF
SUDDEN CARDIAC DEATH
Seven large randomized trials have evaluated the use of
ICDs in patients at risk of sudden cardiac death due to
heart failure or left ventricular dysfunction in the setting
of prior MI (Table 2 and Figure 1) (1,2,10–12,14–16). Each of
the trials evaluated slightly different patient groups, and
all of the trials, with the exception of the Coronary Artery
Bypass Graft (CABG)-Patch trial, identiﬁed a patient
population in whom the ICD conferred a survival beneﬁt
or reduced death from arrhythmia. Of the randomized
trials, the CABG-Patch was unique in that all patients
received revascularization with CABG at the time of ran-
domization. In CABG-Patch, 900 patients with an ejection
fraction (EF) <0.36 and an abnormal signal-averaged ECG
who were undergoing bypass surgery were randomized to
receive an ICD using epicardial patches or not (12). After
an average follow-up of 32 months, the hazard ratio (HR)
for death from any cause was 1.07 (95% conﬁdence
interval [CI]: 0.81–1.42, p ¼ 0.64). ICD implantation was
associated with a higher rate of postoperative infections
(ICD: 12.3% vs control: 5.9%; p < 0.05) and deep sternal
wound infections (ICD: 2.7% vs 0.4%, p < 0.05). Patients
were excluded if they had prior signiﬁcant ventricular
arrhythmias or poorly controlled diabetes. The Multi-
center Unsustained Tachycardia Trial (MUSTT) enrolled
2202 patients with coronary artery disease, an EF #0.40,
and nonsustained ventricular tachycardia (NSVT) $3
beats, of whom 704 had sustained ventricular tachycardia
(VT) inducible by programmed electrical stimulation (10).
The patients with inducible sustained VT were random-
ized to no antiarrhythmic therapy or antiarrhythmic
therapy guided by electrophysiologic (EP) study. After a
median follow-up of 39 months, the 5-year estimates
for overall mortality were 42% and 48%, respectively
(relative risk: 0.80; 95% CI: 0.64–1.01). Within the EP-
guided therapy group, 161 patients received an ICD (after
one or more failed antiarrhythmic drug trials), and in this
TABLE 1
Published Guideline Statements from Professional Societies That Make Recommendations on Implantation of ICDs
Without Cardiac Resynchronization Capabilities
“Secondary Prevention” “Primary Prevention”
2006 ACC/AHA/ESC
Guidelines for
Management of Patients
with Ventricular
Arrhythmias and the
Prevention of Sudden
Cardiac Death
 ICD therapy is recommended for secondary prevention of
SCD in patients who survived VF or hemodynamically
unstable VT, or VT with syncope and who have an
LVEF #40%, who are receiving chronic optimal medical
therapy, and who have a reasonable expectation of survival
with good functional status for more than 1 year.
 An ICD should be implanted in patients with nonischemic
DCM and signiﬁcant LV dysfunction who have sustained VT
or VF, are receiving chronic optimal medical therapy, and
who have reasonable expectation of survival with good
functional status for more than 1 year.
 Coronary revascularization is indicated to reduce the risk of
SCD in patients with VF when direct, clear evidence of
acute myocardial ischemia is documented to immediately
precede the onset of VF.
 If coronary revascularization cannot be carried out and
there is evidence of prior MI and signiﬁcant LV dysfunction,
the primary therapy of patients resuscitated from VF
should be the ICD in patients who are receiving chronic
optimal medical therapy, and who have a reasonable
expectation of survival with a good functional status for
more than 1 year.
 Patients presenting with sustained VT in whom low-level
elevations in cardiac biomarkers of myocyte injury/necrosis
are documented should be treated similarly to patients
who have sustained ventricular tachycardia and in whom
no biomarker rise is documented.
 ICD therapy is recommended for primary prevention to
reduce total mortality by a reduction in SCD in patients
with LV dysfunction due to prior MI who are at least
40 days post-MI, have an LVEF #30%–40%, are NYHA
Class II or III receiving chronic optimal medical therapy,
and have a reasonable expectation of survival with a good
functional status for more than 1 year.
 ICD therapy is recommended for primary prevention to
reduce total mortality by a reduction in SCD in patients
with nonischemic heart disease who have an LVEF #30%–
35%, are NYHA Class II or III, are receiving chronic optimal
medical therapy, and who have reasonable expectation of
survival with good functional status for more than 1 year.
2008 ACC/AHA/HRS
Guidelines for
Device-Based Therapy
 ICD therapy is indicated in patients who are survivors of
cardiac arrest due to VF or hemodynamically unstable
sustained VT after evaluation to deﬁne the cause of the
event and to exclude any completely reversible causes.
 ICD therapy is indicated in patients with structural heart
disease and spontaneous sustained VT, whether hemody-
namically stable or unstable.
 ICD therapy is indicated in patients with clinically relevant,
hemodynamically signiﬁcant sustained VT or VF induced at
electrophysiologic study.
 ICD therapy is indicated in patients with LVEF <35% due to
prior MI who are at least 40 days post-MI and are NYHA
functional Class II or III.
 ICD therapy is indicated in patients with nonischemic DCM
who have an LVEF #35% and who are NYHA Class II or III.
 ICD therapy is indicated in patients with LV dysfunction
due to prior MI who are at least 40 days post-MI, have an
LVEF <30%, and are NYHA functional Class I.
 ICD therapy is indicated in patients with nonsustained VT
due to prior MI, LVEF <40%, and inducible sustained VT at
electrophysiologic study.
2013 ACC/AHA Guideline for
the Management of
Heart Failure
 ICD therapy is recommended for primary prevention of SCD
to reduce total mortality in selected patients with non-
ischemic DCM or ischemic heart disease at least 40 days
post-MI with LVEF of 35% or less and NYHA Class II or III
symptoms on chronic GDMT, who have reasonable
expectation of meaningful survival for more than 1 year.
 ICD therapy is recommended for primary prevention of
SCD to reduce total mortality in selected patients at
least 40 days post-MI with LVEF of 30% or less, NYHA
Class I symptoms while receiving GDMT, who have a
reasonable expectation of meaningful survival for more
than 1 year.
2013 ACC/AHA Guideline for
the Management of
ST-Elevation Myocardial
Infarction
 ICD therapy is indicated before discharge in patients who
develop sustained VT/VF more than 48 hours after STEMI,
provided the arrhythmia is not due to transient or rever-
sible ischemia, reinfarction, or metabolic abnormalities.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; DCM ¼ dilated cardiomyopathy; ESC ¼ European Society of Cardiology; GDMT ¼ guideline-directed medical
therapy; HRS ¼ Heart Rhythm Society; ICD ¼ implantable cardioverter-deﬁbrillator; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; NYHA ¼
New York Heart Association; SCD ¼ sudden cardiac death; STEMI ¼ ST segment elevation myocardial infarction; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular tachycardia.
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(95% CI: 0.27–0.59). In the Multicenter Automatic Deﬁb-
rillator Trial (MADIT), 196 patients with prior myocardial
infarction, EF #0.35, and inducible nonsuppressible
ventricular arrhythmias at electrophysiologic testing were
randomized to receive an ICD or medical therapy alone
(11). After an average follow-up of 27 months, the ICD
was associated with a signiﬁcant reduction in mortality
(HR: 0.46; 95% CI: 0.26–0.82; p ¼ 0.009). In theMulticenter Automatic Deﬁbrillator Trial II (MADIT-II)
1232 patients with an EF #0.30 due to prior myocardial
infarction were randomized to ICD therapy or medical
therapy alone (2). During an average follow-up of 20
months, the ICD was associated with a signiﬁcant reduc-
tion in mortality (HR: 0.69; 95% CI: 0.51–0.93; p ¼ 0.016).
Finally, the Sudden Cardiac Death in Heart Failure Trial
(SCD-HeFT) randomized 2521 patients with an ejection
fraction #0.35 and Class II or III heart failure symptoms to
TABLE 2 Randomized Primary Prevention Trials of ICD therapy: Inclusion Criteria, Enrolled Patients, and Principal Findings
Study Inclusion Criteria Enrolled Patients Findings
Ischemic Cardiomyopathy
Multicenter Automatic
Deﬁbrillator
Implantation Trial
(MADIT) (11)
 Prior MI, LVEF #0.35; NSVT
 Inducible nonsuppressible
sustained VT/VF at EPS
 >3 weeks post-MI
 >2 months post-CABG
 >3 months post-PTCA
 196 patients enrolled, 95 in ICD arm
 Mean age: 63 years
 92% male
 Mean LVEF: 0.26
 90 with prior CABG, 44 with prior PTCA,
53 with $2 prior MIs
 100% NSVT
 Reduced mortality with ICD (HR: 0.46;
p ¼ 0.009)
Coronary Artery Bypass
Graft (CABG) Patch
Trial (12)
 LVEF #0.35, abnormal
SAECG, undergoing CABG
 900 patients enrolled, 446 randomized
to epicardial ICD implantation at time of
CABG
 Mean age: 64 years
 84% male
 Mean LVEF: 0.27
 100% CABG
 No difference in survival with ICD (HR: 1.07;
95% CI: 0.81–1.42; p ¼ 0.64)
 Arrhythmic mortality at 42 months: control
6.9%, ICD 4.0% (p ¼ 0.057) – 45% reduction
in arrhythmic death
 71% of deaths were nonarrhythmic: non-
arrhythmic cardiac mortality at 42 months:
control 12.4%, ICD 13.0% (p ¼ 0.275)
Multicenter Unsustained
Tachycardia Trial
(MUSTT) (10)
 EF #0.40
 NSVT within the last 6
months
 $4 days post-MI or
revascularization
 2202 patients enrolled, 704 patients with
inducible VT, 161 received ICDs
 Median age: 67 years
 90% male
 Median EF: 0.30
 56% prior CABG
 16% within 30 days of an MI
 100% NSVT
 NYHA Class (I/II/II/IV): 37/39/24/0
 Risk of sudden death reduced in patients with
ICDs (HR: 0.24; 95% CI: 0.13–0.45;
p < 0.001)
Multicenter Automatic
Deﬁbrillator
Implantation Trial II
(MADIT-II) (2)
 >21 years old
 EF #0.30
 >1 month after MI
 >3 months after
revascularization
 1232 patients enrolled, 742 in ICD arm
 Median age: 64 years
 84% male
 EF: 0.23
 57% prior CABG
 NYHA Class (I/II/II/IV): 35/35/25/5
 After average f/u of 20 months, ICD group had
lower mortality (HR: 0.69; 95% CI: 0.51–
0.93; p ¼ 0.016)
 ICD associated with an absolute 5.6%
decrease in mortality
Nonischemic
Cardiomyopathy
Deﬁbrillators in Non-
Ischemic
Cardiomyopathy
Treatment Evaluation
(DEFINITE) (16)
 EF <36% due to NICM
 NYHA Class I–III
 NSVT or PVCs
 458 patients enrolled, 229 received ICDs
 Mean age: 58 years
 71% male
 EF: 21%
 NYHA Class (I/II/III): 22/57/21
 216 patients (47%) with a recent diag-
nosis of NICM (#9 months)
 After mean f/u of 29 months, trend for
reduced mortality in the ICD group (HR: 0.65;
95% CI: 0.40–1.06; p ¼ 0.08) and a sig-
niﬁcant decrease in sudden death due to
arrhythmias (HR: 0.20; 95% CI: 0.06–0.71;
p ¼ 0.006)
 Subanalysis showed similar ICD beneﬁt in
patients with recently identiﬁed NICM (<9
months) compared with remote diagnosis
Both Ischemic and
Nonischemic
Cardiomyopathy
Sudden Cardiac Death
in Heart Failure Trial
(SCD-HeFT) (1)
 18 years old
 EF <35%
 NYHA Class II or III
 2521 patients enrolled, 829 received ICDs
 Median age: 60 years
 76% male
 EF: 0.25
 33 patients within 30 days of an MI
 23% NSVT
 NYHA Class (I/II/II/IV): 0/70/30/0
 After median f/u of 46 months, ICD group had
lower mortality (HR: 0.77; 97.5% CI: 0.62–
0.96; p ¼ 0.007) compared with placebo or
amiodarone groups
 ICD associated with an absolute 7.2%
decrease in mortality
Acute Coronary Artery
Disease Deﬁbrillator in
Acute Myocardial
Infarction Trial
(DINAMIT) (14)
 18–80 years old
 MI past 6–40 days
 EF <0.35
 Abnormal HRV
 674 patients enrolled, 332 received ICDs
 Average age: 61 years
 76% male
 EF: 0.28
 Index MI:
 72% Anterior
 72% new Q wave
 Peak CK: 2300 U/L
 Reperfusion: 63%
 26% PCI
 27% thrombolysis
 10% both
 After mean f/u of 30 months, no difference in
mortality between ICD and no ICD groups (HR:
1.08; 95% CI: 0.76–1.55; p ¼ 0.66)
 ICD group had a signiﬁcant decrease in risk of
death due to arrhythmia (HR: 0.42; 95% CI:
0.22–0.83; p ¼ 0.009) but a signiﬁcant
increase in risk of nonarrhythmic death
(HR: 1.75; 95% CI: 1.11–2.76; p ¼ 0.02)
Immediate Risk
Stratiﬁcation
Improves Survival
Study (IRIS) (15)
 MI in the past 5–31 days and
either:
 EF #40% and initial HR
>90 bpm
 NSVT >150 bpm
 898 enrolled, 445 received ICDs
 Average age: 63 years
 77% male
 EF: 0.35
 Index MI:
 64% anterior
 77% STEMI
 Reperfusion: 77%
 72% PCI
 16% thrombolysis (þ/– PCI)
 After mean f/u of 37 months, no difference in
mortality between the ICD and no ICD groups
(HR: 1.04; 95% CI: 0.81–1.35; p ¼ 0.78)
 ICD group had a signiﬁcant decrease in sudden
cardiac death (HR: 0.55; 95% CI: 0.31–1.00;
p ¼ 0.049) but a signiﬁcant increase in risk of
nonsudden cardiac death (HR: 1.92; 95% CI:
1.29–2.84; p ¼ 0.001)
MI ¼ myocardial infarction; LVEF ¼ left ventricular ejection fraction; VT ¼ ventricular tachycardia; VF ¼ ventricular ﬁbrillation; NSVT ¼ nonsustained ventricular tachycardia; CABG ¼
coronary artery bypass grafting; PCI ¼ percutaneous coronary intervention; ICD ¼ implantable cardioverter deﬁbrillator; NYHA ¼ New York Heart Association; HR ¼ hazard ratio;
NICM ¼ nonischemic cardiomyopathy; PVCs ¼ premature ventricular contractions; HRV ¼ heart rate variability; STEMI ¼ ST segment elevation myocardial infarction.
J A C C V O L . 6 4 , N O . 1 1 , 2 0 1 4 Kusumoto et al.
S E P T E M B E R 1 6 , 2 0 1 4 : 1 1 4 3 – 7 7 HRS/ACC/AHA Expert Consensus Statement on ICD therapy
1147
FIGURE 1 Survival Curves for the ICD-Only Primary Prevention Trials in Patients With Cardiomyopathy (CM) Due to Coronary Artery Disease (CAD) or
Acute Myocardial Infarction (MI), Heart Failure, or Nonischemic CM
All curves represent mortality/survival. MADIT ¼ Multicenter Automatic Deﬁbrillator Trial; MUSTT ¼ Multicenter Unsustained Tachycardia Trial;
CABG-Patch ¼ Coronary Artery Bypass Graft-Patch; DINAMIT ¼ Deﬁbrillator in Acute Myocardial Infarction Trial; IRIS ¼ Immediate Risk Stratiﬁcation
Improves Survival Study; SCD-HeFT ¼ Sudden Cardiac Death in Heart Failure Trial; DEFINITE ¼ Deﬁbrillators in Non-Ischemic Cardiomyopathy Treatment
Evaluation Trial. (With Permission New England Journal of Medicine.)
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slightly more than 50% of patients had cardiac dysfunc-
tion and heart failure due to coronary artery disease. After
a median follow-up of 45 months, ICD therapy was asso-
ciated with a signiﬁcant reduction in mortality (HR: 0.77;
97.5% CI: 0.62–0.96; p ¼ 0.007) (1).
It is instructive to examine the clinical characteristics
of patients who were actually enrolled in the trials
(Table 2) (1,2,10–12). The median age of enrolled patients
was 63–67 years, and patients >75 years accounted for 554
(11%) of the patients enrolled in MUSTT, MADIT-I, MADIT-
II, and SCD-HeFT (13). The trials predominantly studied
men, with women accounting for only 8%–24% of
enrollees. Ethnic background was identiﬁed in the MUSTT
and SCD-HeFT trials. Nonwhite patients accounted for 9%
of patients in MUSTT and 24% of patients in SCD-HeFT.
The baseline cardiovascular characteristics varied
between the trials. Although EF was similar for all ﬁve
trials, ranging from 0.23–0.30, 80% of patients in MUSTT
had Class I or II heart failure symptoms, 70% of patients in
MADIT II had Class I or II heart failure symptoms, and 67%
of patients in MADIT and 100% of patients in SCD-HeFT
had Class II or III heart failure symptoms. Prior revascu-
larization with CABG also varied among the three studies,
at approximately 50% of patients with ischemic car-
diomyopathy in SCD-HeFT, 45% in MADIT, 56% in
MUSTT, 57% in MADIT-II, and of course 100% in CABG-
Patch. NSVT was part of the inclusion criteria for MADIT
and MUSTT and thus was present in all patients but was
present in only 23% of patients in SCD-HeFT. The inci-
dence of NSVT was not provided in initial or subsequent
reports on the CABG-Patch or MADIT-II trials.
Two trials have evaluated the use of ICDs in patients in
the acute period after MI (14,15). In the Deﬁbrillator in
Acute Myocardial Infarction Trial (DINAMIT), 674 patients
were randomized between 6 to 40 days after an MI to
receive an ICD or no ICD therapy (14). Additional inclusion
criteria included a left ventricular ejection fraction
(LVEF) #0.35 and impaired cardiac autonomic function.
After a mean follow-up of 30 months, there was no mor-
tality beneﬁt associated with the ICD implant (HR: 1.08;
95% CI: 0.76–1.55; p ¼ 0.66). In the Immediate Risk-
Stratiﬁcation Improves Survival (IRIS) trial, 898 patients
were randomized between 5 to 31 days after an MI to
receive an ICD or no ICD therapy (15). Unlike DINAMIT,
patients could be enrolled in IRIS under two clinical sce-
narios, either an LVEF #0.40 associated with an initial
sinus rate >90 bpm, or NSVT (>3 beats at a rate >150 bpm)
identiﬁed by 24-hour ambulatory ECG. After a mean fol-
low-up of 37 months, ICD therapy was not associated
with a signiﬁcant reduction in mortality (HR: 1.04; 95%
CI: 0.81–1.35; p ¼ 0.78). Similar to the primary prevention
trials discussed previously, both studies predominantly
enrolled men (76%–77%) who were in their early 60s(average age 61–63 years). As expected, the average LVEF
was higher in IRIS (0.35) when compared with DINAMIT
(0.28) because 23% of patients were enrolled in IRIS based
on the presence of NSVT. In both studies, anterior wall
MIs accounted for two-thirds of the index MIs. Reperfu-
sion therapy in DINAMIT was performed in approximately
60% of patients, evenly split between thrombolysis and
percutaneous coronary intervention (PCI). Reperfusion
therapy was attempted in 77% of patients in IRIS, with
three-fourths of these patients receiving PCI.
Two large studies on ICD therapy in patients with non-
ischemic cardiomyopathy have been completed (1,16). In
SCD-HeFT, 1211 patients (slightly less than 50% of the total
group) had heart failure due to nonischemic cardiomyop-
athy (1). In a prespeciﬁed analysis of this patient group,
ICD therapy conferred a trend toward a survival advantage
(HR: 0.73; 97.5% CI: 0.50–1.07; p ¼ 0.06). The apparent
decrease in the magnitude of beneﬁt conferred by the ICD
is in part explained by the lower event rate observed in
patients with nonischemic cardiomyopathy when com-
pared with patients with ischemic cardiomyopathy (5-year
event rate with ICD therapy: ischemic 0.359 vs non-
ischemic 0.214). The Deﬁbrillators in Non-Ischemic Car-
diomyopathy Treatment Evaluation (DEFINITE) trial
evaluated only patients with nonischemic cardiomyop-
athy (16). A total of 458 patients with nonischemic car-
diomyopathy, LVEF <0.36, and frequent premature
ventricular contractions or NSVT were randomized to ICD
therapy or no ICD therapy. After a mean follow-up of 29
months, there was a trend toward improved survival with
ICD (HR: 0.64; 95% CI: 0.40–1.06; p ¼ 0.08) and a sig-
niﬁcant reduction in deaths due to arrhythmia with ICD
therapy (HR: 0.20; 95% CI: 0.06–0.71; p ¼ 0.006). The
patients enrolled in DEFINITE were younger (average age
58 years) and had a lower ejection fraction (0.21) than the
patients enrolled in the trials that evaluated the beneﬁts of
ICD therapy in patients with coronary artery disease.
4. ICD IMPLANTATION IN THE CONTEXT OF AN
ABNORMAL TROPONIN THAT IS NOT DUE TO A
MYOCARDIAL INFARCTION
Patient Population #1: Patients with an abnormal troponin
level (or other biomarker for myocardial infarction) who
do not fulﬁll criteria for MI, and previously satisﬁed
primary prevention or secondary prevention criteria for
ICD implantation.
Recommendation:
 In patients with abnormal cardiac biomarkers that are
not thought to be due to an MI and who otherwise
would be candidates for implantation on the basis of
primary prevention or secondary prevention criteria,
implantation of an ICD is recommended.
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unique and speciﬁc set of clinical and laboratory criteria.
The detection of elevated cardiac biomarkers alone is not
sufﬁcient to satisfy this deﬁnition.
The diagnostic criteria for acute MI, established by
the joint ESC/ACC/AHA/WHF Task Force, are the follow-
ing (17):
An appropriate rise and/or fall in cardiac biomarkers
with at least one value above the 99th percentile
upper reference level, together with evidence of
myocardial ischemia and with at least ONE of the
following:
 Electrocardiographic evidence of new ischemia (ST
segment shift or development of left bundle branch
block [LBBB])
 Evolution of pathologic Q waves on the
electrocardiogramFIGURE 2 Ischemic and Nonischemic Causes of Abnormal Troponin
ACS ¼ acute coronary syndrome; AMI ¼ acute myocardial infarction; CAD ¼ coro
CT ¼ cardiothoracic; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary i
myocardial infarction. (From Newby et al. [17]. Used with permission from the A Imaging evidence of new regional wall motion abnor-
mality or new loss of viable myocardium
 Ischemic symptoms
Cardiac biomarkers (MB fraction of creatine kinase
[CKMB] or troponin) can rise in clinical circumstances
other than acute myocardial infarction, such as kidney
disease, acute pulmonary embolus, heart failure, myo-
carditis, chest trauma, or tachyarrhythmia. These bio-
markers have been reviewed in the ACC 2012 expert
consensus document on practical clinical considerations
in the interpretation of troponin elevations (Figure 2) (18).
The diagnosis of MI implies myocyte necrosis due to an
ischemic insult and should be reserved for patients who
satisfy the above diagnostic criteria. Patients who do not
meet these criteria need to be evaluated quite differently
in terms of suitability for ICD therapy. The requirement to
delay ICD implantation for 40 days after presentation isnary artery disease; CHF ¼ congestive heart failure; CM ¼ cardiomyopathy;
ntervention; PE ¼ pulmonary embolism; STEMI ¼ ST segment elevation
merican College of Cardiology.)
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established. This mandatory waiting period should not be
imposed on patients who would otherwise qualify for an
ICD for either primary or secondary prevention.
5. ICD IMPLANTATION WITHIN 40 DAYS OF A
MYOCARDIAL INFARCTION
In the greatmajority of situations, ICD implantation should
be performed at least 40 days after an MI. During the acute
phase of MI, it is often unclear how much recovery of
cardiac function will occur following hospital discharge,
and in some cases, the clinical condition is so severe that
ICD implantationwould be of little value. The 2008 Device-
Based Guidelines emphasize this point, largely based on
the negative results of DINAMIT and later conﬁrmed by the
publication of IRIS (5). Despite the results of these clinical
trials, the writing group identiﬁed several scenarios in
which clinicians may consider implanting an ICD withinFIGURE 3 ICD Implantation Within 40 days of Myocardial Infarction
ICD ¼ implantable cardioverter-deﬁbrillator; LVEF ¼ left ventricular ejection fra
VT ¼ ventricular tachycardia.40 days of an MI (Figure 3). For each of these scenarios we
will review the data pertaining to this topic and provide
Consensus Recommendations for ICD implantation.
Patient Population #2: Patients within 40 days of acute
MI who have known left ventricular dysfunction and who
have previously satisﬁed criteria for implantation of a
primary prevention ICD.
Recommendation:
 Implantation of an ICD within the ﬁrst 40 days fol-
lowing acute MI in patients with preexisting systolic
ventricular dysfunction (who would have qualiﬁed for
a primary prevention ICD) is not recommended.
Discussion: Patients who present an acute coronary
syndrome can have preexisting left ventricular dysfunc-
tion due to prior ischemic events or a cardiomyopathic
process. The 6-month period immediately following an
acute MI confers a high risk of sudden death (19,20). Inction; MI ¼ myocardial infarction; NYHA ¼ New York Heart Association;
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IANT), the risk of sudden death was highest in the ﬁrst 30
days after an MI, at 1.4% per month, and decreased to
0.14% per month after 2 years (20).
A survival advantage was clearly demonstrated in the
MADIT-II trial for patients receiving ICD therapy after MI
(2). The study population included patients with an MI >1
month from study entry and an LVEF #0.30. There was no
requirement for electrophysiologic testing. However, as
illustrated by the survival curves in Figure 1, the beneﬁt
did not become evident until approximately 9 months
after device implantation. Similarly, separation of the
survival curves in SCD-HeFT was also observed 12–15
months after device implantation (Figure 1) (1).
Given the high risk of sudden death in the early post-MI
period and the beneﬁts of ICD therapy in patients with
cardiac dysfunction due to MI, it would seem intuitive
that ICD implantation early after MI would be beneﬁcial.
However, two separate randomized trials have failed to
show an advantage to ICD implantation within 30–40 days
after MI (DINAMIT, IRIS) (14,15). The DINAMIT trial failed
to show early survival beneﬁts in patients who underwent
ICD implantation within 6–40 days of an acute infarct.
There was a highly statistically signiﬁcant reduction in
the incidence of arrhythmic death (95% CI: 0.22–0.83; p ¼
0.009) for patients receiving an ICD. This was balanced,
however, by an increased incidence of nonarrhythmic
death; thus, overall survival was not improved (14).
Patients in IRIS were enrolled within 1 month of the index
infarction, and once again there was a 45% lower risk of
sudden death in the ICD group. However, this lower risk
was offset by a signiﬁcantly increased risk of non-
arrhythmic death in the control patients (p ¼ 0.001) (15).
Although DINAMIT and IRIS did not speciﬁcally study the
patient population in question (implantation of an ICD
following an acute MI with preexisting systolic dysfunc-
tion), neither provided evidence of a survival advantage
conferred by early implantation of an ICD.
Subsequent analysis of VALIANT and DINAMIT has
provided a likely pathophysiologic mechanism for the
absence of beneﬁt of ICD implantation in the early period
after myocardial infarction (21,22). In DINAMIT, only
50% of the sudden deaths were attributable to arrhyth-
mia, whereas mechanical causes of SCD (e.g., LV rupture,
acute mitral regurgitation) were observed in the other half
of patients (21). Similarly in VALIANT, investigators
evaluated the available autopsy records in patients who
experienced sudden death (22). In the ﬁrst month after
MI, 80% of sudden cardiac deaths appeared to be due to
recurrent MI or rupture, and presumed arrhythmia death
only accounted for the remaining 20% of sudden cardiac
deaths. By 1 year, the proportions of sudden deaths due
to nonarrhythmia vs arrhythmia causes were equal, and
over time there appeared to be a very gradual increasein the proportion of sudden deaths due to arrhythmia
(approximately 60% at 30 months). Therefore, it would
not be anticipated that early implantation of an ICD in this
patient population would signiﬁcantly impact these
deaths. It can also be argued that early ICD implantation
in these patients can actually “cause harm” and neg-
atively impact survival. Ventricular remodeling following
an acute MI can produce new substrates for ventricular
arrhythmia. Patients randomized to ICD therapy in the
DINAMIT study who died were those who received shocks
for ventricular arrhythmias. These patients also had more
recurrent myocardial ischemia and more heart failure
events (21). Supporting this hypothesis is a retrospective
subanalysis of patients who received ICDs and subsequent
shocks in MADIT-II (23). Patients randomized to ICD ther-
apy had a signiﬁcant increase in the risk of ﬁrst heart failure
events (HR: 1.39; p ¼ 0.02) that was more pronounced in
those patients who received shocks (HR: 1.9; p ¼ 0.01). The
study authors postulated that deﬁbrillator shocks can
result in injury to the myocardium, and that ventricular
function can be further impaired as a consequence of
backup ventricular pacing. Finally, a review of a large sin-
gle-center database of 16,793 patients who were referred to
the cardiac catheterization laboratory for acute manage-
ment of MI found a 90-day cardiovascular mortality rate of
9%, with 75% of the deaths judged to be coronary artery
disease-related nonsudden death, 9% coronary artery dis-
ease-related sudden death, and 4% due to sudden death
not related to coronary artery disease (24).
Aggressive therapy to reduce the risk of sudden cardiac
death in the early period after MI directed toward revas-
cularization and improvement in left ventricular function
and clinical heart failure can be a more prudent and
effective strategy as compared with early ICD implanta-
tion. Although the ACC/HRS/AHA/ASE/HFSA/SCAI/SCCT/
SCMR 2013 Appropriate Use Criteria for Implantable
Cardioverter-Deﬁbrillators and Cardiac Resynchroniza-
tion Therapy have provided “appropriate” scores (8 and
9) for ICD implantation in this patient population, the
consensus of this group is that implantation of an ICD
is not recommended within the ﬁrst 40 days after the
MI unless other potential reasons for an ICD implant
are present (patient populations 3–6) (9).
Patient Population #3: Patients within 40 days of an
acute MI who also have an indication for permanent
pacemaker implantation.
Recommendation:
 In patients who, within 40 days of an MI, require
nonelective permanent pacing, who also would meet
primary prevention criteria for implantation of an ICD,
and recovery of left ventricular function is uncertain or
not expected, implantation of an ICD with appropri-
ately selected pacing capabilities is recommended.
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clearly direct the clinician to identify the rhythm abnor-
malities that require pacing support in patients following
MI (5). In the presence of normal or mildly reduced left
ventricular function there would be no rationale for
expanding the guidelines to include ICD therapy. In the
circumstance in which the patient’s LVEF is #0.35 (or
LVEF #0.40 with ambient NSVT and positive EP study),
one needs to consider whether using an ICD platform
when implanting the permanent pacemaker (PPM) is
reasonable. This reﬂects the fact that implantation of a
pacemaker or ICD is associated with some risk, especially
infection. If the likelihood that a patient requiring PPM
implantation early post-MI will ultimately require a sec-
ond procedure to extract the PPM and leads and replace it
with an ICD system 40 days later, it would seem inap-
propriate not to implant an ICD rather than a PPM.
Therefore, if a patient requires urgent nonelective
implantation of a PPM within 40 days of an MI, and
recovery of ventricular systolic function is uncertain or
not anticipated, implantation of an ICD platform with
appropriately selected pacing capability is appropriate.
This approach not only avoids subjecting the patient to a
second procedure and its attendant risks, it also lowers
total cost. The choice of a single, dual, or biventricular
system should be based upon the clinical setting, current
guidelines, and consensus documents that address this
decision under general conditions. The 2013 AUC docu-
ment for ICDs also gives an “appropriate” score in this
situation (9).
In contrast to the scenario outlined above, if recovery
of ventricular contractility can be anticipated with a
high degree of certainty, then it would be appropriate to
implant a PPM. Similarly, if pacemaker implantation
for heart rate support can be delayed, it is prudent to
wait until recovery of left ventricular function can be
assessed.
Patient Population #4: Patients within 40 days of an MI
who subsequently present sustained or hemodynamically
signiﬁcant ventricular tachyarrhythmias.
Recommendations:
 In patients who, within 40 days of an MI, develop
sustained (or hemodynamically signiﬁcant) ventricular
tachyarrhythmias >48 hours after an MI and in the
absence of ongoing ischemia, implantation of an ICD is
recommended.
 In patients who, within 40 days of an MI, develop
sustained (or hemodynamically signiﬁcant) VT >48
hours after an MI that can be treated by ablation,
implantation of an ICD can be useful.
 In patients who, within 40 days of an MI, develop
sustained (or hemodynamically signiﬁcant) ventricular
tachyarrhythmias where there is clear evidence of anischemic etiology with coronary anatomy amenable to
revascularization (and appropriately treated), implan-
tation of an ICD is not recommended.
Discussion: The risk of ventricular tachyarrhythmias in
patients with acuteMI is highest at the time of presentation
and declines over the hours and days that follow (19).
Several studies have evaluated the frequency and
prognosis associated with sustained ventricular tachyar-
rhythmias in the setting of an ST segment elevation MI
(STEMI) (25–28). In the Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarcto Miocardico (GISSI-2) data-
base, the incidence of early-onset (#4 hours) and later (>4
to 48 hours) sustained VT or ventricular ﬁbrillation (VF)
was 3.1% and 0.6%, respectively (25). Patients who
developed early VF had a more complicated course than
matched controls, and development of VF, regardless of
timing, was an independent predictor of in-hospital
mortality. However, the postdischarge to 6-month death
rates were similar for those patients who developed VF
and those patients who did not. In an analysis of 40,895
patients enrolled in the Global Use of Streptokinase tPA
for occluded coronary arteries (GUSTO-1) trial, 4188
(10.2%) had signiﬁcant sustained ventricular tachyar-
rhythmias split approximately evenly between VF and VT
(26). Patients with ventricular tachyarrhythmias had
higher in-hospital mortality rates (VT: 19%; VF: 24%;
both: 44%) and 30-day mortality rates (VT: 18%; VF: 24%;
both: 45%) than patients without ventricular tachyar-
rhythmias (in-hospital mortality: 4.2%; 30-day mortality:
4.6%). Among patients who survived hospitalization, no
signiﬁcant difference was found in the 30-day mortality
between the ventricular tachyarrhythmia and no ven-
tricular arrhythmia groups. However, in patients who
survived at 30 days, 1-year mortality rates were higher in
patients with VT (7.2%) or both VT and VF (7.1%) when
compared with the patients with either VF (2.9%) or nei-
ther type of arrhythmia (2.7%). In general, developing
sustained ventricular tachyarrhythmias >2 days after
hospital admission was associated with a poorer prog-
nosis (1-year mortality in 30-day survivors: VT: 24.7%, VF:
6.1%, both: 4.7%). More recently, in an analysis of the
Assessment of Pexelizumab in Acute Myocardial Infarc-
tion (APEX-MI) trial, 5.7% of patients presenting STEMI
had sustained ventricular tachyarrhythmias, with 90% of
ventricular tachyarrhythmias occurring within the ﬁrst 48
hours (27). In a multivariate analysis, patients with early
ventricular tachyarrhythmias had a higher heart rate,
Killip class, and total ST segment deviation. At 90 days,
mortality was higher for patients with ventricular
tachyarrhythmias compared with those patients without
ventricular tachyarrhythmias (23.6% vs 3.6%, adjusted
HR: 3.63; 95% CI: 2.59–5.09). Of the patients who devel-
oped sustained ventricular tachyarrhythmias, ventricular
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catheterization in two-thirds of the patients, while the
remaining third developed ventricular tachyarrhythmias
after leaving the cardiac catheterization laboratory. The
90-day mortality rate was signiﬁcantly higher in those
patients who developed ventricular tachyarrhythmias
after leaving the cardiac catheterization laboratory (33%)
compared with those patients who developed ventricular
tachyarrhythmias before or during cardiac catheterization
(17%). Finally, in an analysis of the pooled data from the
four Primary Angioplasty in Myocardial Infarction (PAMI)
trials, approximately 4% of patients developed sustained
ventricular tachyarrhythmias during PCI (28). In-hospital
and 4-year mortality were similar between patients who
developed sustained ventricular tachyarrhythmias during
PCI and those patients who did not.
Increased mortality is also observed in patients who
develop ventricular tachyarrhythmias in the setting of a
non-ST segment elevation MI (NSTEMI). The PURSUIT
trial evaluated the impact of a glycoprotein IIb/IIa inhib-
itor on mortality or myocardial infarction patients with
NSTEMI (29). In this population, the onset of either VT or
VF was associated with an increase in 30-day mortality
(HR: 23.2). Similarly, in an analysis of the Early Glyco-
protein IIb/IIIa Inhibition in NSTE ACS (EARLY ACS) trial,
sustained ventricular tachyarrhythmias were observed in
1.5% of patients, with 0.6% occurring #48 hours after
enrollment (30). The risk of death at 1 year relative to
patients without ventricular tachyarrhythmias was dra-
matically greater in those patients with ventricular
tachyarrhythmias >48 hours (HR: 20.7; 95% CI: 15.39–
27.85) when compared with patients with ventricular
tachyarrhythmias #48 hours (HR: 7.45; 95% CI: 4.60–
12.08).
The development of ventricular tachyarrhythmias after
the acute phase depends in large part on the extent of left
ventricular dysfunction. Patients enrolled in the VALIANT
trial with an LVEF #0.30 demonstrated the highest inci-
dence of early cardiac arrest or sudden death (20). In a
subsequent analysis of the 164 patients who had suc-
cessful resuscitation after sudden death in VALIANT, 75
had cardiac arrest within the ﬁrst 40 days after myo-
cardial infarction (31). Investigators felt that ICD implan-
tation would have been beneﬁcial in 16 of these patients,
with a median time of 11 days between cardiac arrest and
ICD implant. ICD implantation was associated with a
nonsigniﬁcant decrease in mortality (HR: 0.44; 95% CI:
0.10–2.01; p ¼ 0.29), although the sample size was small
and would have only identiﬁed a very large beneﬁt in
terms of mortality. Although the AVID trial allowed
enrollment of patients within 5 days of a myocardial
infarction, and 67% of patients had a history of myo-
cardial infarction, it is not clear how many patients were
enrolled within 40 days of a myocardial infarction.In addition, it is notable that more than 60% of patients
had no angina prior to the event, and patients who were
thought to have a transient or correctable cause for ven-
tricular tachyarrhythmias were enrolled in the registry
rather than the main trial (3).
These data indicate that patients with ventricular
tachyarrhythmias following MI are at risk of catastrophic
events such as cardiac arrest or sudden death, and that
the risk is highest within the ﬁrst 30–60 days following
MI. This is particularly true for patients with left ven-
tricular systolic dysfunction. Implantation of an ICD in
this population is reasonable in selected patients in the
absence of opportunities for revascularization. When
there is evidence of reversible ischemia that is responsible
for the ventricular tachyarrhythmia, revascularization
options need to be implemented as an initial strategy
before committing the patient to ICD therapy. In partic-
ular, VF that occurs within the ﬁrst several hours after the
onset of symptoms of an acute MI has not been associated
with an increased risk of late sudden cardiac death.
Finally, some ventricular tachyarrhythmias can be effec-
tively treated with catheter ablation (32). In patients with
idiopathic VT (e.g., right ventricular outﬂow tract tachy-
cardia), catheter ablation would effectively eliminate the
arrhythmia and ICD therapy is not required. However,
even patients with VT easily amenable to ablation (e.g.,
bundle branch reentry) can remain at signiﬁcant risk of
other ventricular tachyarrhythmias due to the presence of
structural heart disease, and the clinician must decide
whether an ICD is appropriate on an individual basis.
Patient Population #5: Patients who, within 40 days of
an MI (but >48 hours), present with syncope likely due to
ventricular tachyarrhythmia, and in whom there is no
evidence of ongoing ischemia.
Recommendation:
 In patients who, within 40 days of an MI, present with
syncope that is thought to be due to ventricular
tachyarrhythmia (by clinical history, documented
NSVT, or electrophysiologic study), implantation of an
ICD can be useful.
Discussion: Patients with syncope in the setting of
structural heart disease have an increased incidence of
sudden death and overall mortality (6,8,9). The ACC/
AHA/HRS 2008 Guidelines for Device-Based Therapy
specify a Class I indication for ICD implant for “patients
with syncope of undetermined origin with clinically rel-
evant, hemodynamically signiﬁcant sustained VT or VF
induced at electrophysiological study” (5). This recom-
mendation is based primarily on the Canadian Implant-
able Deﬁbrillator Study (CIDS), which speciﬁcally
included unmonitored syncope patients either who were
later identiﬁed as having spontaneous VT of at least 10
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morphic VT (33). It is important to note that these inclu-
sion criteria were applicable for only 87 of the 659
patients enrolled in CIDS, and the point estimate was
approximately 0.95 with very wide conﬁdence intervals.
The 2006 Guidelines on Ventricular Arrhythmias provide
a Class I recommendation for an EP study for the diag-
nostic evaluation of patients with a remote MI with
symptoms suggestive of ventricular tachyarrhythmias
such as syncope (6). Performance of an EP study appears
to be safe after myocardial infarction, and inducible
monomorphic VT does appear to identify a group with
higher mortality (34). No study has speciﬁcally evaluated
the use of an EP study in patients with syncope in the ﬁrst
40 days after a myocardial infarction.
Based on our literature search, we have identiﬁed no
studies that have speciﬁcally addressed whether ICD
implantation is beneﬁcial in the setting of syncope
thought to be due to a ventricular tachyarrhythmia in the
ﬁrst 40 days after MI. However, the consensus of the
writing group is that syncope in the setting of a recent MI
is a potentially serious issue, and ICD implantation can be
useful if syncope is thought to be due to a ventricular
tachyarrhythmia (by clinical history, documented NSVT,
or EP study), regardless of timing in relationship to an MI
(either <40 days or $40 days after MI).
Patient Population #6: Patients within 40 days of an MI
who have a previously implanted ICD that requires elective
replacement for battery depletion.
Recommendation:
 In patients within 40 days of an MI and who have an
ICD that requires elective replacement due to battery
depletion, after careful assessment of comorbidities
and the current clinical situation, replacement of the
ICD generator is recommended.
Discussion: An ICD approaching the end of its service is
typically replaced. The absence of ICD shock or a
requirement for antitachycardia therapies during the ﬁrst
battery service period does not indicate that an ICD is no
longer required. There is evidence that up to 14% of
patients who receive an ICD for primary prevention and
whose ﬁrst battery period is uneventful will require
device therapy in the following 2.5 years (35).
In patients who undergo ICD implantation for primary
prevention, the indication for device therapy persists
following MI, particularly if there has been further dete-
rioration of left ventricular function. Similarly, patients
who receive device therapy for secondary prevention
should be eligible for generator replacement following
MI. In addition, the original indications for ICD implan-
tation should be reviewed. The clinician needs to apply
clinical judgment to determine whether there are newcomorbidities that impact life expectancy in making this
decision.
Patient Population #7: Patients with signiﬁcant left
ventricular dysfunction within 40 days following an acute
MI who are also listed for heart transplantation or who
undergo implantation of a left ventricular assist device.
Recommendation:
 ICD implantation in patients within 40 days of an
MI who have been listed for heart transplant or
implanted with a left ventricular assist device is not
recommended.
Discussion: There is very little scientiﬁc evidence
available to address this issue. Patients presenting
refractory heart failure and/or hemodynamic instability
typically require mechanical support such as a ventricular
assist device (VAD) or extracorporeal membrane oxygen-
ation (ECMO). Implantation of an ICD in this scenario is
rarely a consideration because there is no clear evidence
of beneﬁt.
There are a few studies that have evaluated the beneﬁt
of ICD therapy following resuscitated sudden death or
as primary prevention in patients waiting for transplant
(36–41). However, most of these studies are fairly small
and nonrandomized. There are certainly no data to sup-
port ICD therapy in patients within 40 days of an MI who
are waiting for cardiac transplant. Large clinical trials
such as SCD-HeFT and MADIT-II did not include patients
with Class IV heart failure (1,2). In addition, the survival
beneﬁt with ICD implantation was not observed until 1
year after enrollment. Given the associated risk of non-
sudden cardiac death and the higher likelihood of sudden
death not due to ventricular arrhythmias, ICD implanta-
tion in patients within the ﬁrst 40 days after MI who are
waiting for transplant is not supported by current evi-
dence. The wearable cardioverter-deﬁbrillator (WCD) may
be an option as a “bridge to ICD” for selected patients
at high risk of sudden cardiac death due to ventricular
arrhythmias, although the data are scant (42).6. ICD IMPLANTATION WITHIN 90 DAYS OF
REVASCULARIZATION
Patient Population #8A: Patients within 90 days of
revascularization who have known left ventricular dys-
function and who have previously satisﬁed criteria for
implantation of a primary prevention ICD.
Recommendation:
 In patients who are within 90 days of revascularization
and who previously qualiﬁed for the implantation of an
ICD for primary prevention of sudden cardiac death,
and who have undergone revascularization that is
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and who are not within 40 days after an acute MI,
implantation of an ICD can be useful.
Discussion: An analysis of the survival beneﬁt with an
ICD in the ﬁrst 90 days after revascularization is lacking
from the large, randomized, primary prevention trials. In
their study designs, MADIT excluded subjects within
2 months after CABG and 3 months after PTCA, and
MADIT-II excluded subjects within 3 months after revas-
cularization (2,11). Conversely, early revascularization
was permitted in MUSTT, which enrolled subjects at least
4 days after revascularization, and SCD-HEFT made no
speciﬁc exclusion with respect to the timing of revascu-
larization (1,10). However, in SCD-HEFT, the median time
from CABG to enrollment was 3.1 years, and from PCI to
enrollment was 2.3 years. Therefore, the published
device-based therapy guidelines do not speciﬁcally
address ICD implantation within 90 days of coronary
revascularization for patients who otherwise meet ICD
implant criteria for primary prevention of sudden cardiac
death (5).
Revascularization has important time-dependent ben-
eﬁts. In the untreated arm of MUSTT, 228 subjects had
postoperative NSVT (within 30 days after CABG) and 1302
had nonpostoperative NSVT (in patients who had no prior
CABG or who were at least 30 days after CABG) (43). The
postoperative NSVT group had slower VT, higher LVEF
(0.30 vs 0.28, p ¼ 0.002), shorter time from most recent
MI, less heart failure, and higher use of beta-blockers and
aspirin, but more multivessel coronary artery disease,
lower use of Angiotensin Converting Enzyme inhibitors
(ACE), diuretics, calcium channel blockers, and nitrates.
This group had a lower inducibility rate for sustained
monomorphic VT (27% vs 33%) and lower rates of 2- and
5-year arrhythmic events (6% vs 15% at 2 years, 16% vs
29% at 5 years) and overall mortality (15% vs 24% at 2
years, 36% vs 47% at 5 years). Substudies of the primary
prevention trials (MADIT-II, MADIT-CRT, and SCD-HEFT)
show that an ICD has an increasing survival beneﬁt
as time from revascularization increases (44–46). In a
MADIT-II substudy of 951 patients with prior coronary
revascularization, an ICD was of beneﬁt only in patients
enrolled at least 6 months after revascularization (45). In
another MADIT-II substudy of 563 patients who received
an ICD and underwent coronary revascularization, for
every year that elapsed from coronary revascularization
there was an associated 6% increase in 8-year mortality
and a 5% increase in appropriate ICD therapy (46). In a
substudy of MADIT-CRT, the rate of VT/VF or death
was lower early (<1.5 years) compared with later
after revascularization (44). Finally, a SCD-HeFT sub-
study of ischemic heart disease patients not randomized
to amiodarone showed that prior PCI was associated withreduced mortality risk and CABG was associated with
reduced sudden death risk, with a trend for improved
survival if CABG occurred more than 2 years prior to
enrollment (47). A retrospective observational study of
patients with ischemic cardiomyopathy who underwent
CABG also showed an improved survival for patients who
subsequently were implanted with an ICD than those who
did not receive an ICD, with a mean time to implant in ICD
patients of 2 years (48). However, a limitation of these
studies was that they analyzed patients several months to
years from revascularization, and not within 90 days from
revascularization. An exception was the CABG-Patch trial
that randomized patients to ICD therapy using epicardial
leads or no ICD at the time of CABG. There was no dif-
ference in survival with an ICD (HR 1.07; 95% CI:
0.81–1.42; p ¼ 0.64), although there was a 45% borderline
signiﬁcant reduction in arrhythmic death (p ¼ 0.0570)
(12,49). In a subanalysis of CABG-Patch, patients with
poorer left ventricular function as assessed by a wall
motion score #16% (using centerline chord motion anal-
ysis from a ventriculogram) showed improved survival
when treated with an ICD (ICD 4 year-survival: 0.72 vs no
ICD 4-year survival: 0.56; p ¼ 0.046) (50). In this analysis,
although patients had poorer left ventricular function as
assessed by a wall motion score, LVEF was not sig-
niﬁcantly different by left ventricular angiography
emphasizing the difﬁculties in assessing left ventricular
function.
The risk of sudden death early after revascularization is
unclear. As mentioned above, in a substudy of MUSTT,
patients enrolled within 30 days of CABG had signiﬁcantly
lower rates of arrhythmic events and total mortality,
despite other high-risk characteristics, than patients not
enrolled within 30 days after CABG. In a substudy of the
Beta-Blocker Evaluation of Survival Trial (BEST), patients
with ischemic heart failure (LVEF #35%) and prior CABG
also had lower all-cause mortality, but sudden cardiac
death was unchanged when compared with propensity-
matched patients without CABG (51). Furthermore,
patients with signiﬁcantly reduced left ventricular func-
tion display poor survival early (within the ﬁrst few
months) after coronary revascularization. Weintraub et al.
(52) reported mortality results after PCI, linking PCI data
from the CathPCI National Cardiovascular Data Registry
(NCDR) to the Centers for Medicare and Medicaid Services
(CMS) database. In this study of 343,466 patients aged
$65 years undergoing ﬁrst PCI in the CathPCI Registry, a
high early phase hazard of death was observed in survival
curves in patients with LVEF <0.30. Similarly, Shahian
et al. (53) reported mortality results in 348,341 isolated
CABG patients $65 years of age, linking data from the
Society of Thoracic Surgeons (STS) Adult Cardiac Surgery
Database to the CMS database. Early mortality risk was
also evident in patients with LVEF <0.30. The proportion
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revascularization that is due to arrhythmic death is
unknown. Nonrandomized, retrospective studies, how-
ever, have suggested a beneﬁt of ICD implant early after
coronary revascularization (54–57).
The WCD may play a role in patients at risk of sudden
cardiac death in the early period after revascularization.
In a recently published retrospective evaluation of 4958
patients with EF #0.35 after CABG and PCI from two
combined databases, 809 patients who were discharged
with a WCD were compared to the remaining 4149
patients (58). The WCD was associated with a lower
90-day mortality in patients after CABG (no WCD: 7% vs
WCD: 3%) and after PCI (no WCD: 10% vs WCD: 2%). For
the entire WCD group, 18 appropriate deﬁbrillations
occurred in 11 patients (12% of patients discharged with a
WCD). Inappropriate shocks accounted for 42% of the
therapies delivered.
An electrophysiologic study with programmed stim-
ulation may play a role in identifying patients at risk of
developing sustained ventricular tachyarrhythmias after
revascularization, although the results from small obser-
vational studies have been mixed. In an observational
study of 109 consecutive patients who had NSVT 2–66
days after PCI or CABG with a mean ejection fraction of
0.30, sustained monomorphic VT was induced in 42% of
patients and an ICD was implanted (55). During a mean
follow-up of 27 months, 33% of patients with an ICD had
appropriate therapy, and more relevant to this discussion,
16% of patients developed VT/VF or sudden cardiac death
in the ﬁrst year of follow-up. In another retrospective
study of 69 patients who received an ICD within 4 months
of surgery, inducible ventricular tachyarrhythmia was not
identiﬁed as a variable for predicting appropriate ICD
therapy or mortality, although the numbers were small
(54).
The rationale for waiting 90 days after revasculariza-
tion to implant an ICD is based upon the premise that LV
function can improve sufﬁciently to raise the LVEF to
above 0.35. It remains a major challenge to predict those
patients who will or will not signiﬁcantly improve their
LV function. In patients with LV dysfunction before
CABG, persistent LV dysfunction after CABG with
LVEF #0.35 has been reported in 25%–74% of patients
(54,57). In one recent study of patients with reduced LVEF
(<0.40) undergoing CABG, 30% of patients had improve-
ment in left ventricular function, although only 6% had
an improvement of $0.05 units on repeat assessment 9–12
months after revascularization (59). Various preoperative
imaging studies can predict improvement in post-
operative LVEF and survival outcomes in patients who
have signiﬁcant regions of ischemic or hibernating but
viable myocardium and who are adequately revascular-
ized (60,61). However, in the Surgical Treatment forIschemic Heart Failure (STICH) trial, identiﬁcation of
viability preoperatively failed to identify patients with a
differential survival beneﬁt from CABG as compared
to medical therapy alone (62). Nonetheless, imaging
studies have shown utility for predicting arrhythmias;
several single-center studies have demonstrated that
cardiac Magnetic Resonance Imaging (MRI) incorporating
late gadolinium enhancement (LGE-CMR) can assess and
quantify myocardial scars and predict future ventricular
tachyarrhythmias, including appropriate ICD therapies in
both primary and secondary prevention patients (63–67).
If improvement of LVEF is suspected on clinical grounds,
repeat imaging prior to ICD implantation can provide
important information for the decision process. Since
institutions and speciﬁc methods for measuring LVEF
vary, similar techniques should be used when possible if
serial measurements of the LVEF are required.
There is high early mortality demonstrated in patients
with low LVEF despite coronary revascularization. Thus,
in patients who previously qualiﬁed for the implantation
of an ICD for primary prevention of sudden cardiac
death and who have undergone revascularization that is
unlikely to result in an improvement in LV ejection
fraction >0.35, and who are not within 40 days after
an acute MI, implantation of an ICD can be useful
(Figure 4).
Patient Population #8B: Patients within 90 days of
revascularization who have previously satisﬁed criteria for
implantation of a secondary prevention ICD (resuscitated
from cardiac arrest due to VT/VF).
Recommendations:
 In patients within 90 days of revascularization who
have previously qualiﬁed for the implantation of an
ICD for secondary prevention of sudden cardiac death
(resuscitated from cardiac arrest due to ventricular
tachyarrhythmia) and have abnormal left ventricular
function, implantation of an ICD is recommended.
 In patients within 90 days of revascularization who
have previously qualiﬁed for the implantation of an
ICD for secondary prevention of sudden cardiac death
(resuscitated from cardiac arrest due to ventricular
tachyarrhythmia) that is unlikely related to myocardial
ischemia/injury and have normal left ventricular
function, implantation of an ICD is recommended.
 In patients within 90 days of revascularization who
have previously qualiﬁed for the implantation of an
ICD for secondary prevention of sudden cardiac death
(resuscitated from cardiac arrest due to ventricular
tachyarrhythmia) that was not related to acute myo-
cardial ischemia/injury and who were subsequently
found to have coronary artery disease that is revascu-
larized with normal left ventricular function, implan-
tation of an ICD can be useful.
FIGURE 4 ICD Implantation Within 90 Days of Revascularization
ICD ¼ implantable cardioverter-deﬁbrillator; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; VT ¼ ventricular tachycardia.
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were resuscitated from cardiac arrest due to ventricular
tachyarrhythmia that was related to acute myocardial
infarction/injury, with normal left ventricular function,
and who undergo complete coronary revascularization,
an ICD is not recommended.
Discussion: Patients who met ICD implant criteria for
secondary prevention of sudden cardiac death (resusci-
tated from pulseless VT or VF) prior to coronary revas-
cularization are likely to remain at high risk after
revascularization unless the initial ventricular tachyar-
rhythmia event was clearly related to an acute MI and
treated with complete revascularization of the ischemic
region with complete normalization of LV function. In
patients resuscitated from cardiac arrest that was not in
the setting of an acute MI or in the setting of myocardial
scarring, there is likely to remain a myocardial substrate
that is vulnerable to recurrent ventricular tachyar-
rhythmias following revascularization, even if the LVEF
were to improve to >0.35. In the AVID trial, 10% of ICD
patients and 12% of patients randomized to drugs
underwent coronary revascularization, and revasculari-
zation did not alter survival (3). This outcome issupported by an analysis of patients in the AVID Registry,
who had life-threatening ventricular tachyarrhythmias
due to transient or correctable causes. The majority of
such patients were regarded as having myocardial ische-
mia as a correctable cause and underwent revasculariza-
tion as primary therapy, yet still remained at high risk of
death in follow-up, with mortality no different or perhaps
even poorer than that of the primary ventricular
tachyarrhythmia population randomized in the main
AVID study (68). In another analysis of the AVID Registry,
both revascularization and ICD implantation improved
survival, but the survival beneﬁt of an ICD was inde-
pendent of revascularization (69). Nonrandomized
observational or retrospective studies of ICD implantation
early after revascularization in secondary prevention
patients have also reported similar event rates to those of
primary prevention studies, including early occurrence of
ventricular tachyarrhythmias and appropriate ICD thera-
pies (57,70–72). In an observational study of 58 patients
who underwent CABG at the time of deﬁbrillator implant,
LVEF #0.30 was an independent predictor of deﬁbrillator
discharge (73). An earlier observational study showed
survival in cardiac arrest survivors undergoing CABG
(without ICD implant) to be excellent if LV function was
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viously qualiﬁed for the implantation of an ICD for sec-
ondary prevention of sudden cardiac death (resuscitated
from cardiac arrest due to ventricular tachyarrhythmia)
likely related to myocardial ischemia/injury, and have
abnormal left ventricular function, an ICD is recom-
mended. If left ventricular function is normal and the
cardiac arrest is likely related to myocardial ischemia/
injury that is revascularized, implantation of an ICD can
be useful. If the cardiac arrest is unlikely to be related to
myocardial ischemia/injury, an ICD is recommended.
Patient Population #9: Patients within 90 days of
revascularization who also have an indication for PPM
implantation.
Recommendation:
 In patients within 90 days of revascularization who
require nonelective permanent pacing, who would also
meet primary prevention criteria for implantation of
an ICD, and in whom recovery of left ventricular
function is uncertain or not expected, implantation of
an ICD with appropriately selected pacing capabilities
is recommended.
Discussion: Approximately 1.5% of patients undergoing
cardiac surgery will require a PPM prior to discharge
(75–78). Known predictors include conduction abnormal-
ities prior to surgery and type of surgery, including aortic
valve replacement, tricuspid valve replacement, and
atrial ﬁbrillation surgery (75,79). In patients who require
ventricular pacing, biventricular pacing may be needed if
ventricular pacing is likely to exceed 40% in patients with
an LVEF #0.35, in accordance with the 2012 ACC/AHA/
HRS Update of the 2008 Guidelines for Device-Based
Therapy as a Class IIa indication (8). Patients enrolled in
the major biventricular pacing trials (Multicenter InSync
ICD Randomized Clinical Evaluation [MIRACLE], MUlti-
site STimulation in cardiomyopathy [MUSTIC], Compar-
ison of Medical Therapy, Pacing, and Deﬁbrillation in
Heart Failure [COMPANION], Cardiac Resynchronization-
Heart Failure [CARE-HF], and Multicenter Automatic
Deﬁbrillator Implantation With Cardiac Resynchroniza-
tion Therapy [MADIT-CRT]) were primarily at least 3
months from prior revascularization (80–84). An excep-
tion was the Resynchronization-Deﬁbrillation for Ambu-
latory Heart Failure Trial (RAFT), which allowed patients
with recent revascularization; patients needed to be at
least 1 month from revascularization (CABG or PCI) if the
LVEF was >0.30, but could have more recent revascula-
rization provided the LVEF was #0.30 (85).
However, when faced with the need for permanent
pacing and the signiﬁcant likelihood that revasculariza-
tion will not result in an LVEF >0.35, the primary
implantation of an ICD will avoid the need for a secondprocedure to upgrade a pacemaker to an ICD, which has
been associated with a higher risk of complications
(54,57). In the REPLACE prospective registry of compli-
cations after implanted cardiac device replacement or
upgrades, major complications occurred in 4.0% of 1031
patients undergoing generator replacement and 15.3% of
713 patients undergoing device replacement/upgrades
with addition of a lead (86). Major complications were
higher with ICD compared with pacemaker generator
replacements, and were highest in patients who had an
upgrade to or a revised cardiac resynchronization therapy
device (18.7%).
In patients who require urgent, nonelective permanent
pacing following revascularization (CABG or PCI) within
the past 90 days with an LVEF #0.35, an ICD is recom-
mended. The choice of a single, dual, or biventricular
system should be based upon the clinical setting, current
guidelines and consensus statements that address this
decision under general conditions, and patient preference
(5,8,87).
Patient Population #10: Patients within 90 days of
revascularization who subsequently present sustained or
hemodynamically signiﬁcant ventricular tachyarrhythmia.
Recommendations:
 In patients within 90 days of revascularization
with structural heart disease and sustained (or hemo-
dynamically signiﬁcant) ventricular tachyarrhythmia
that was not clearly related to acute myocardial
infarction or ischemia, implantation of an ICD is
recommended.
 In patients who, within 90 days of revascularization,
develop sustained (or hemodynamically signiﬁcant) VT
that can be treated by ablation therapy, implantation of
an ICD can be useful.
Discussion: The survival beneﬁt of an ICD for patients
with symptomatic sustained VT (not in the setting of
cardiac arrest) speciﬁcally as a cause for syncope or
associated with an ejection fraction below 0.40 has been
previously demonstrated in the AVID trial (3). Sympto-
matic sustained ventricular tachycardia without cardiac
arrest was also included in CIDS, while the Cardiac Arrest
Study Hamburg (CASH) required all ventricular arrhyth-
mias to be associated with cardiac arrest (33,88). As a
result, the 2008 ACC/AHA/HRS Guidelines for Device-
Based Therapy specify ICD implant as a Class I indication
for patients with “structural heart disease and sponta-
neous sustained VT, whether hemodynamically stable or
unstable” (5). An additional Class IIa recommendation is
made for ICD implant in patients with “sustained VT and
normal or near-normal ventricular function” (5). It is
important to note that the recommendations do not have
any time constraints.
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further and independent survival beneﬁt to patients with
sustained ventricular tachyarrhythmias (not related to a
cardiac arrest) who undergo revascularization. In a small,
retrospective, single-center study that followed 93
patients with VT or VF felt to be due to myocardial
ischemia and who underwent CABG, the long-term sur-
vival was excellent over 8 years at 88%, though survival
was not compared between patients with and without an
ICD (70). However, this conclusion is challenged by data
from the AVID registry of patients not randomized to the
main study (69). Wyse et al. (68) examined the long-term
follow-up of patients in the AVID registry regarded to
have VT or VF that was secondary to a transient or cor-
rectable cause, which was most commonly myocardial
ischemia, comprising 65.8% of the 278 patients analyzed.
Compared with a cohort of 2013 registry patients with out-
of-hospital primary VT or VF, patients thought to have a
correctable cause had a higher mortality after adjustment
for covariates, including revascularization. This study did
not separately analyze outcomes according to index
arrhythmia.
Predictors of an appropriate ICD shock in relationship to
revascularization were reported in a single-center retro-
spective study of 591 patients, of whom 73 patients had VT
and 77 patients had syncope (89). These authors found in a
multivariate analysis that HRs for ICD shock were lower
in CABG patients, but higher in patients with left ven-
tricular enlargement. The incremental beneﬁt of an ICD
for revascularized patients was best explored in another
AVID registry substudy that analyzed a cohort of 2202
patients, of whom 281 patients underwent CABG after the
index arrhythmic event (patients with PCI were excluded)
(69). Ventricular tachycardia was the index event in 39%
of revascularized patients and 58% of nonrevascularized
patients (p < 0.001). ICDs were implanted more commonly
in patients who were not revascularized (51% vs 42%,
p ¼ 0.006). Registry patients who underwent CABG had
improved survival, with an adjusted HR of 0.67 (p ¼ 0.011).
However, an ICD gave a further survival advantage inde-
pendent of revascularization. In this study as well, anal-
ysis according to the index arrhythmia was not made, but
a large fraction of the patients studied had VT.
Patients with VT can be considered for EP study
because VT may be completely treated by ablation ther-
apy; in the situation where VT is treated by ablation, an
ICD can still be considered, as recurrence rates can be
high. In all other patients with structural heart disease
and sustained (or hemodynamically signiﬁcant) VT or VF
that is not clearly related to acute MI, implantation of an
ICD is recommended.
Patient Population #11: Patients within 90 days of
revascularization who present with syncope likely due to
ventricular tachyarrhythmia.Recommendation:
 In patients within 90 days of revascularization present
with syncope that is thought to be due to ventricular
tachyarrhythmia (by clinical history or documented
NSVT, or EP study), implantation of an ICD can be
useful.
Discussion: The evaluation of patients with syncope can
be challenging. Patients with NSVT pose concerns that
syncope is due to sustained VT. However, even in patients
with structural heart disease, syncope might still be
nonarrhythmic in its etiology. Therefore, a careful eval-
uation of the syncope patient is needed. The presence of
structural heart disease with reduced LV ejection fraction
or inducibility for VT at EP study is highly suggestive that
syncope is due to ventricular tachyarrhythmia.
Therefore, it is our recommendation that in patients
with syncope that is likely due to ventricular tachyar-
rhythmia either by documentation of NSVT or inducible
VT at EP study, implantation of an ICD can be useful
regardless of the timing of past revascularization.
Patient Population #12: Patients within 90 days of
revascularization who have a previously implanted ICD
that requires elective replacement due to battery depletion.
Recommendation:
 In patients within 90 days of revascularization with an
ICD that requires replacement due to battery depletion,
after careful assessment of comorbidities and the cur-
rent clinical situation, replacement of the ICD gen-
erator is recommended.
Discussion: The number of patients with an ICD in place
at the time of cardiac surgery is currently unknown.
However, with the increase in congestive heart failure,
the number of ICD patients undergoing revascularization
is likely to increase. No data exist regarding the risk of
sudden cardiac death in patients with an ICD at its end
of life within the ﬁrst 90 days of revascularization, yet
there remains the concern that the very early post-
revascularization (PCI or CABG) time period is one of
increased total mortality risk (52,53).
Therefore, we recommend that the ICD patient whose
generator is at its end of service due to battery depletion
undergo generator replacement regardless of the timing
of revascularization.
Patient Population #13: Patients within 90 days of
revascularization who are also listed for heart trans-
plantation or who undergo implantation of a ventricular
assist device.
Recommendation:
 In patients within 90 days of revascularization who
have been listed for heart transplant or implanted with
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days of an acute myocardial infarction, implantation of
an ICD can be useful.
Discussion: The ACC/AHA/HRS 2008 Guidelines for
Device-Based Therapy specify a Class IIa indication for
the implantation of an ICD in nonhospitalized patients
who are awaiting heart transplantation (5). It is a Class III
indication by those guidelines if patients are NYHA Class
IV with drug-refractory heart failure and are not candi-
dates for transplant or biventricular pacing. The exclusion
to allow an ICD in the setting of biventricular pacing is
due to the inclusion of ambulatory Class IV heart failure
patients in the COMPANION trial who improved in func-
tional status and survival with CRT-D therapy (82). In the
recent 2012 update, it is now a Class I recommendation to
implant a biventricular ICD in ambulatory Class IV
patients with LBBB and QRS duration $150 ms (8).
Patients who are considered candidates for transplant
pose other considerations. However, it is implicit in the
listing for the transplant that there are no other treat-
ments that have been successful or that are expected to
meaningfully reverse the patient’s status, including
revascularization. Even if revascularization has been
performed in the recent past, the listing for transplant
should be taken as implying that revascularization was
inadequate or failed.
The literature relating to the beneﬁt of ICD implants in
patients awaiting transplant include observational retro-
spective analyses from single centers from the 1990s and
early 2000s showing improved survival for patients
awaiting transplant with an ICD, with survival curves
separating within the ﬁrst 3 months (36–39). In an analysis
of 310 patients awaiting transplant at the University of
Minnesota, the overall mortality in ICD patients was 22%
compared with 60.2% in non-ICD patients, and both ICD
implant and beta-blockade were protective (38). Survival
at 6 months and at 1, 2, 3, and 4 years was signiﬁcantly
improved in ICD patients (p ¼ 0.0001). In an analysis of
854 patients awaiting transplant in Europe and with a
median follow-up of 4.7 months, total mortality in ICD
patients was 11.8% compared with 21.5% in non-ICD
patients (p ¼ 0.03) (39). Of note, the indication for ICD
implant in these studies was largely for secondary
prevention.
In recent years, literature on large cohorts of patients
with VADs has emerged (90,91). Many of these patients
are awaiting transplant, but an increasing proportion
receive assist devices as lifetime therapy or to allow fur-
ther time to determine eligibility for transplantation. The
ﬁrst postoperative month is recognized as a period of
increased risk of ventricular tachyarrhythmias (92,93).
However, the risk of ventricular arrhythmias persists
beyond this immediate postoperative period, and in anobservational study of 478 VAD patients from the Cleve-
land Clinic, of whom 90 patients had an ICD, one-third of
patients had their ﬁrst arrhythmic event beyond 30 days
postoperation (90). Furthermore, survival was improved
in ICD patients (p ¼ 0.024), and they were more likely to
survive to transplant (p ¼ 0.015). Survival curves in these
studies separate early between ICD and non-ICD patients,
within the ﬁrst 3 months. Of note, the majority of patients
in these studies received a left ventricular assist device
(LVAD), and the arrhythmic risk and protection afforded
by an ICD can be attenuated in patients with a biven-
tricular assist device (BIVAD) (91).
The LVAD confers some protection from hemodynamic
collapse during ventricular tachycardia or ﬁbrillation.
However, the lack of adequate right ventricular function
compromises ﬁlling of the left ventricle and the assist
device. Although death with VT or VF is less likely than
without LVAD support, syncope can occur, sometimes
with signiﬁcant head injury. Demonstration of better
survival with ICDs in the VAD patients from observational
studies might reﬂect in part the better prognosis for
patients with ICDs for chronic heart failure than for
patients with new acute hemodynamic collapse leading to
urgent VAD placement. Patients with a BIVAD generally
tolerate even ventricular ﬁbrillation and are unlikely to
derive survival beneﬁt from an ICD prior to transplant.
In light of the demonstrated improved survival with an
ICD, particularly emerging within the ﬁrst few months, we
consider an ICD implant to be useful in outpatients
awaiting transplant or with a VAD who are not <40 days
from MI. Since revascularization in such patients is
implied to have been unsuccessful, the timing of any
recent revascularization should not be a deterrent to the
implantation of an ICD.
7. ICD IMPLANTATION <9 MONTHS FROM THE
INITIAL DIAGNOSIS OF NONISCHEMIC
CARDIOMYOPATHY
Patient Population #14: Patients <9 months from the ini-
tial diagnosis of nonischemic cardiomyopathy (NICM) who
have signiﬁcant left ventricular dysfunction and heart
failure symptoms.
Recommendations:
 Implantation of an ICD for primary prevention is not
recommended within the ﬁrst 3 months after initial
diagnosis of NICM.
 If recovery of left ventricular function is unlikely,
implantation of an ICD for primary prevention can be
useful between 3 and 9 months after initial diagnosis of
NICM.
Discussion: Historically, before the widespread use of
many established therapies, the 5-year mortality for NICM
Kusumoto et al. J A C C V O L . 6 4 , N O . 1 1 , 2 0 1 4
HRS/ACC/AHA Expert Consensus Statement on ICD therapy S E P T E M B E R 1 6 , 2 0 1 4 : 1 1 4 3 – 7 7
1162was estimated to be 50%, and 30% of the deaths were
sudden (4,6). Although ventricular tachyarrhythmias are
the most common cause of sudden death, bradycardia and
pulseless electrical activity can also cause sudden death,
particularly in those patients with advanced disease (94).
The primary challenge in deciding whether or when to
implant an ICD is distinguishing between patients who
are recently diagnosed with previously unrecognized
chronic cardiomyopathy and those patients whose car-
diomyopathy is truly of recent onset. The initiation and
titration of optimal medical therapy often improves LVEF
out of range of primary ICD indications, but this is par-
ticularly true for patients with less than 6 months
of disease (Table 3). In the Intervention in Myocarditis
and Acute Cardiomyopathy (IMAC)-2 study, 373 patients
with new-onset cardiomyopathy (LVEF #0.40, <6 months
from initial diagnosis) were followed for 4 years (95).
Transplant-free survival at 4 years was 88%, and mor-
tality at 4 years was 4%. In addition to improved survival,
70% of patients had an absolute increase in LVEF of 10%,
and 25% of patients had complete or near-complete (LVEF
>0.50) resolution of their cardiomyopathy. Approx-
imately one-third of the deaths were sudden, and eight
patients were hospitalized for ventricular arrhythmias
during the follow-up period. In the Marburg Cardiomy-
opathy Study, 343 patients with NICM from a single center
were followed for more than 4 years. During the study
period, 33 patients (13%) died and 10 patients (4%) under-
went cardiac transplant (96). Major arrhythmic events,
deﬁned as sustained VT, VF, or sudden cardiac death, were
observed in 46 patients (13%). LVEF was the only sig-
niﬁcant independent risk factor for a major arrhythmicTABLE 3 Relevant Studies in NICM
Natural History of SCD in NICM
Grimm et al. (MACAS) (96)
 343 patients with EF <0.45 and an LVED
 Overall sudden death rate of 6.7%
 At 9 months, arrhythmia-free survival an
for LVEF >0.30
McNamara et al., Sheppard et al.
(IMAC-2) (95,102)
 373 patients with LVEF <0.40 for less t
 At 6 months, 92% on an ACEI, 94% on
 At 6 months, 70% had an absolute incre
 At 6 months, 40% with an EF >0.45 an
 No difference in mortality with the ICD R
 Six patients with sudden death at a mea
Zecchin et al. (103)  Analysis of 503 patients from the Heart
 Complete data on 287 patients
 245 with EF #0.35 and $Class II NYHA
 31% remained with EF #0.35 and NYHA
 227 with EF >0.35 or Class I NYHA hear
 10% had progression to EF <0.35 and in
 2% sudden death rate between initial vi
Effect of Timing of ICD Implantation
Kadish et al. (100)
 458 patients with NICM, EF <0.36 and u
 150 patients <3 months from diagnosis
 Similar ICD beneﬁt regardless of the tim
Makati et al. (101)  131 patients with NICM divided into two
 ICD treated arrhythmias in 27% in both
ACEI ¼ angiotensin converting enzyme inhibitor; BB ¼ beta blocker; ICD ¼ implantable cardio
left ventricular end-diastolic diameter; LVEF ¼ left ventricular ejection fraction; MACAS ¼ Ma
Heart Association.event, with each 10% decrease in EF associated with a 2.3
fold increase in risk. A later subanalysis of the data sug-
gested that longer episodes of NSVT ($10 beats) were
associated with a higher risk of major arrhythmia events
(no NSVT: 2% per year; 5- to 9-beat runs of NSVT: 5% per
year; $10 beat runs of NSVT: 10%; p < 0.05) (97).
Four randomized studies have evaluated the use of
ICDs in patients with NICM (1,16,98,99). The two largest
trials, the DEFINITE trial and the SCD-HeFT, showed a
decrease in arrhythmia-related death associated with
ICD use (1,16). Two smaller randomized studies on ICD
use in NICM were performed before DEFINITE and SCD-
HeFT. In the Cardiomyopathy Trial (CAT), 104 patients
with newly identiﬁed NICM (within 9 months of initial
diagnosis) and Class II/III heart failure were randomized
to ICD therapy or no ICD therapy (98). The initial
assumptions used for trial design included a 30% mor-
tality rate at 1 year, and a 1-year 6% absolute beneﬁt
from ICD therapy. The actual observed 1-year mortality
rate was only 6% in the ﬁrst 104 patients, and the trial
was stopped prematurely. In the Amiodarone Versus
Implantable Cardioverter-Deﬁbrillator Randomized Trial
(AMIOVIRT), 103 patients with NICM (LVEF #0.35) and
NSVT were randomized to ICD therapy or amiodarone
(99). The study was stopped prematurely, in this case
because the prospective rule for futility was reached.
There was no difference in survival between the two
therapies (amiodarone 1-year survival: 90% vs ICD 1-year
survival: 96%). There was no speciﬁc time from initial
diagnosis to enrollment in AMIOVIRT, although the
average duration of NICM was 3 years prior to enroll-
ment into the trial.D >56 mm followed for 52 months
d transplant-free survival of approximately 5% for LVEF <0.30 and 2%–3%
han 6 months
a BB, and 20% with an ICD
ase in EF by >10 EF “units” and 39% had an increase of 20 U
d 25% with a normal EF
x
n 420 days (range 23–1059 days)
Muscle Registry of Trieste initially evaluated between 1988 and 2006
heart failure symptoms
symptoms after Rx and 5 months f/u
t failure
creased symptoms
sit and follow-up in both groups
nsustained ventricular arrhythmias
to randomization, 66 between 3 and 9 months, and 242 >9 months
e between diagnosis and randomization
cohorts: <9 months vs >9 months from symptom onset
groups
verter-deﬁbrillator; IMAC ¼ Intervention in Myocarditis and Cardiomyopathy; LVEDD ¼
rburg Cardiomyopathy Study; NICM ¼ nonischemic cardiomyopathy; NYHA ¼ New York
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1163All three of the current guidelines that address the use
of ICD therapy for primary prevention of sudden cardiac
death in NICM (ACC/AHA/ESC 2006 Guidelines for the
Management of Patients with Ventricular Arrhythmias
and the Prevention of Sudden Cardiac Death, ACC/AHA/
HRS 2008 Guidelines for Device-Based Therapy, and the
2009 Focused Update of the ACC/AHA 2005 Guidelines for
the Diagnosis and Management of Heart Failure) are
consistent and recommend ICD therapy for patients with
NICM, Class II or III heart failure, and an LVEF #0.35
(4–6). None of the guidelines have a time constraint on
the duration of nonischemic cardiomyopathy, but the
2006 Ventricular Arrhythmias Guideline emphasize the
importance of “chronic optimal medical therapy” and the
2008 Guidelines for Device-Based Therapy emphasize
that reversible causes for transient left ventricular func-
tion be excluded, response to optimal medical therapy be
assessed, and that “physicians should consider the timing
of deﬁbrillator implantation carefully” (6). The 2013
Appropriate Use Criteria for ICD Therapy are more
expansive and classify ICD therapy as “appropriate” in
NICM >3 months on guideline-directed therapy for
LVEF #0.40 in the setting of NYHA Class I–III symptoms,
and “may be appropriate” #3 months in patients with
LVEF #0.30 and NYHA Class II or III symptoms (9).
The relationship between the beneﬁt of ICD implanta-
tion and the duration of NICM has been evaluated in sev-
eral studies. In the DEFINITE study, the average duration
of NICM prior to randomization was almost 3 years (16).
In a subsequent subanalysis that compared outcomes
between patients with #3 months’ duration (n ¼ 150) vs
patients >3 months’ duration (n ¼ 308), and between
patients #9 months (n ¼ 216) vs patients >9 months
(n ¼ 242), the investigators found similar beneﬁts asso-
ciated with ICD implant regardless of duration of NICM
(100). It is important to note that patients were not
randomized in the trial if they were thought to have a
potentially reversible cause of cardiomyopathy such as
peripartum cardiomyopathy, myocarditis, or acute drug-
induced cardiomyopathy. Similarly, in a single-center
study of 131 patients with NICM and ICDs, a similar fre-
quency of arrhythmias appropriately treated with ICDs
was found in the 52 patients with diagnosis of NICM <9
months (27%) when compared with the 79 patients with
NICM $9 months (27%) (101). In contrast, in a subanalysis
of IMAC-2, early ICD placement did not have an impact
on survival (102).
Analysis of the IMAC-2 patient cohort emphasizes the
dynamic nature of left ventricular function in some
patients with the recent diagnosis of NICM. Similarly, in a
cohort from an Italian registry of 245 patients with newly
identiﬁed NICM who would qualify for an ICD on the basis
of symptoms and ejection fraction, 109 patients demon-
strated improvement in their left ventricular function atthe 9-month follow-up (103). It might be that even with
improvement in left ventricular function, patients remain
at risk of ventricular arrhythmias. In a recently published
subanalysis of the DEFINITE trial, 187 patients had a
follow-up echocardiography for assessment of left ven-
tricular function (104). Of these, 96 patients (51%) had an
absolute improvement in LVEF >5%, 79 patients (42%)
had no change in LVEF, and 12 patients (6%) had an
absolute decrease in LVEF >5%. Patients with improve-
ment in LVEF had signiﬁcant improvement in survival
when compared with patients with no change in LV
function (HR: 0.22; 95% CI: 0.06–0.82; p ¼ 0.023) and
worsening LV function (HR: 0.09; 95% CI: 0.02–0.39; p ¼
0.001). In addition, patients with improved LV function
had fewer arrhythmic events (HR: 0.47; 95% CI: 0.22–1.02;
p ¼ 0.049), but 5.7% of patients had signiﬁcant ven-
tricular tachyarrhythmias even after the ejection fraction
improved to >0.35.
Separating patients who will have improvement in left
ventricular function, a decrease in overall mortality, and a
decreased risk of sudden death from those patients with
irreversible or progressive left ventricular dysfunction is
difﬁcult. In the IMAC-2 study, at initial evaluation,
smaller left ventricular end-diastolic diameter, higher
systolic blood pressure, and an acute inﬂammatory proc-
ess identiﬁed at biopsy were associated with an increased
likelihood of recovery of left ventricular function (95).
Conversely, black race and higher NYHA functional class
were associated with a lower EF at follow-up. Myocardial
ﬁbrosis in the mid-wall of the left ventricle identiﬁed by
magnetic resonance imaging might provide some addi-
tional prognostic information on the potential reversi-
bility of cardiomyopathy (105). In a cohort of 472 patients,
142 patients (30%) had mid-wall ﬁbrosis, and during a
median follow-up of 5.3 years, these patients had a higher
risk of mortality (HR: 2.96; 95% CI: 1.87–2.96) and a higher
risk of sudden death (HR: 4.61: 95% CI: 2.75–7.74; p <
0.001) (104). Genetic testing can also play a role in risk
stratiﬁcation of patients with NICM (105). Preliminary
studies suggest that NICM due to LMNA, TNNT2, SGCD,
RBM20, and CHRM2 mutations can be at higher risk of
sudden cardiac death (106–110). Patients with cardiac
sarcoidosis and LVEF <0.30 are unlikely to improve with
medical therapy (111). Giant cell myocarditis is a rare
cause of myocarditis characterized by large multi-
nucleated cells and has an extremely virulent course that
does not respond to therapy (112).
Taken collectively, the data suggest that a signiﬁcant
proportion of patients with the new diagnosis of NICM will
have improvement in left ventricular function, but some
patients will remain at risk of ventricular arrhythmias.
The clinician must carefully evaluate those patients with
relatively recent onset NICM, and ICD implantation for
primary prevention between 3 and 9 months can be useful
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1164in selected patients with NICM who are unlikely to have
recovery of left ventricular function. Patients with sarcoi-
dosis, giant cell myocarditis, or familial cardiomyopathy
with a family history of sudden death might beneﬁt from
ICD implantation during this period. The improvement
in left ventricular function found in the IMAC-2 study
emphasizes the importance of aggressive appropriate
medical treatment. In patients with NICM <9 months it is
generally prudent to delay ICD until the full effect of
medical therapy can be evaluated. Implantation of an
ICD is not recommended within the ﬁrst 3 months after
the initial diagnosis of NICM unless other potential reasons
for ICD implant are present (populations 15–18) (Figure 5).FIGURE 5 Indications for ICD Implantation in Patients With a Diagnosis of
ICD ¼ implantable cardioverter-deﬁbrillator; LVEF ¼ left ventricular ejection fraPatient Population #15: Patients <9 months from the
initial diagnosis of NICM who meet criteria for primary
prevention ICD who also have an indication for PPM
implantation.
Recommendation:
 In patients <9 months from the initial diagnosis of
NICM who require nonelective permanent pacing, who
would meet primary prevention criteria for implanta-
tion of an ICD, and recovery of left ventricular function
is uncertain or not expected, implantation of an ICD
with the appropriately selected pacing abilities is
recommended.Nonischemic Cardiomyopathy Less Than 9 Months
ction; NYHA ¼ New York Heart Association; VT ¼ ventricular tachycardia.
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1165Discussion: Some patients can develop NICM and
atrioventricular (AV) conduction abnormalities over a
relatively short time. Muscular dystrophies are a group of
inherited disorders of skeletal muscles with diverse pre-
sentations that can sometimes confront the clinician with
difﬁcult decisions. Duchenne, Becker, and limb-girdle
types 2C-2F and 2I are associated with dilated cardiomy-
opathy and increased risk of ventricular tachyar-
rhythmias, and are associated with progressive AV
conduction disorders that are generally proportional to
the amount of left ventricular dysfunction present (107).
Patients with myotonic dystrophy Type 1 also can present
with cardiomyopathy and progressive AV block. In the
largest registry published to date, 406 patients with
genetically conﬁrmed myotonic dystrophy were followed
for 9.5 years (108). Forty-six patients received pace-
makers for conduction abnormalities and 21 patients
received ICDs primarily for LV dysfunction. During fol-
low-up, seven patients in the pacemaker group had sud-
den cardiac death and 6.5% of patients had sudden death
due to ventricular tachyarrhythmias compared with no
patients in the group who received ICDs.
Mutations of the lamin A/C (LMNA) gene can be asso-
ciated with a variety of cardiac abnormalities such as
cardiomyopathy, atrial and ventricular tachyarrhythmias,
and conduction tissue disease; and extracardiac mani-
festations such as skeletal muscle abnormalities and
premature aging. In an early small series of 19 patients
with LMNA gene mutations who were initially referred for
pacemaker implantation and who underwent ICD
implantation, during a mean follow-up of 34 months, 42%
of patients received appropriate ICD therapy (109). No
factor, including LVEF, presence of spontaneous or
inducible ventricular tachyarrhythmias, or drug therapy,
was associated with appropriate ICD therapy. In a recently
published multicenter cohort of 269 patients with LMNA
mutations, approximately 35%–40% had cardiomyopathy
(EF <0.45) and almost 50% had AV block (113). In the 152
patients who did not have an ICD, sudden death occurred
in 13 patients (9%) compared to 1 of 117 patients who
received ICDs. Twenty-eight of 117 patients (24%)
received appropriate ICD therapy.
Patients with cardiac sarcoidosis or giant cell myo-
carditis can also present with AV block. In a single-center
evaluation of 133 patients aged 18–55 who underwent
pacemaker implantation for a second- or third-degree AV
block, 18 patients (14% of the entire cohort and 25% of
patients with unexplained AV block) had cardiac sarcoi-
dosis or giant cell myocarditis and had an average LVEF of
0.52 with a range of 0.25–0.70 (114). During an average 4-
year follow-up, LVEF decreased (0.43, range 0.15–0.65),
and from this original group, 4 died, 4 had VF, 6 had
sustained VT, and 1 patient underwent transplant for
recurrent uncontrollable ventricular tachyarrhythmias.No patients in the IMAC-2 trial presented with con-
comitant AV block, although 20% presented with LBBB
(92). The ACC/AHA/HRS 2008 Device-Based Guidelines
provide recommendations for pacing system implanta-
tion, and the ACC/HRS 2012 Consensus Statement on
Pacing Mode provides information on appropriate pacing
mode (5,87). To reduce the morbidity associated with
possible additional procedures, for patients with the
recent diagnosis of NICM (<9 months) who also have an
urgent and nonelective indication for permanent pacing,
initial implantation of an ICD with appropriate pacing
capabilities is recommended, particularly in the presence
of accompanying AV block.
Patient Population #16: Patients <9 months from the
initial diagnosis of NICM who also have sustained or
hemodynamically signiﬁcant ventricular tachyarrhythmia.
Recommendation:
 In patients <9 months from the initial diagnosis of
NICM with sustained (or hemodynamically signiﬁcant)
ventricular tachyarrhythmia, implantation of an ICD is
recommended.
Discussion: Patients who present sustained or hemo-
dynamically signiﬁcant ventricular tachyarrhythmias in
the setting of NICM are at high risk for a subsequent event.
In a small study of 54 patients with NICM who received an
ICD for sustained VT or sudden cardiac death, during
32-month follow-up, 28 patients (52%) received appro-
priate ICD therapy (115). In this cohort, 21 of 28 patients
had therapy for VF, and the average time between ICD
implant and ﬁrst appropriate therapy was 9 months.
ICD therapy is beneﬁcial in patients who have sus-
tained or hemodynamically signiﬁcant ventricular tachy-
cardia with NICM <9 months. The clinical guidelines do
not include time constraints for secondary prevention ICD
implantation (Table 1).
Patient Population #17: Patient <9 months from the
initial diagnosis of NICM who present with syncope likely
due to ventricular tachyarrhythmia.
Recommendation:
 In patients <9 months from the initial diagnosis of
NICM with syncope that is thought to be due to a ven-
tricular tachyarrhythmia (by clinical history or docu-
mented NSVT), implantation of an ICD can be useful.
Discussion: Single-center studies have evaluated the
natural history of patients with syncope in the setting of
NICM (116,117). In a single-center study performed two
decades ago, of 491 patients with advanced heart failure
due to coronary artery disease (48%) and NICM (51%), 60
patients (12%) had syncope (116). During a mean follow-
up of 1 year, the incidence of sudden death was higher in
the syncope group compared with those patients without
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1166syncope (syncope: 45% vs no syncope: 12%; p < 0.00001).
In another single-center study that compared 108 patients
with syncope in the setting of NICM with 71 patients who
had NICM and sustained ventricular tachyarrhythmias,
no differences in overall survival or risk of ventricular
arrhythmias could be identiﬁed, and the risk of develop-
ing ventricular tachyarrhythmias was 26%–41% (117).
Unfortunately, traditional methods for risk strat-
iﬁcation are generally less useful in patients with NICM.
The ACC/AHA/ESC 2006 Guidelines for Management of
Patients with Ventricular Arrhythmias and the Prevention
of Sudden Cardiac Death note that: “In DCM (dilated
cardiomyopathy), EP testing plays a minor role in the
evaluation and management of VT. This recommendation
is related to the low inducibility, low reproducibility of EP
testing, and low predictive value of induced VT” (6).
The ACC/AHA/ESC 2006 Guidelines for Management
of Patients with Ventricular Arrhythmias and the Pre-
vention of Sudden Cardiac Death and the ACC/AHA/HRS
2008 Guidelines on Device-Based Therapy are consistent
and provide a Class IIa recommendation for ICD therapy
in patients with unexplained syncope and left ventricular
dysfunction in the setting of NICM (5,6). The ACC/AHA/
ESC 2006 Ventricular Arrhythmias Guidelines further
stipulate that the patient must be receiving “chronic
optimal medical therapy” and have a “reasonable
expectation of survival with a good functional status for
more than 1 year” (6).
Patient Population #18: Patients <9 months from the
initial diagnosis of NICM who are also listed for heart
transplantation or who undergo implantation of a ven-
tricular assist device.
Recommendation:
 In patients <9 months from the initial diagnosis of
NICM who have been listed for heart transplant or
implanted with a left ventricular assist device,
implantation of an ICD can be useful.
Discussion: There are scant data on the use of ICDs in
patients with the recent diagnosis of NICM who have been
listed for heart transplant or have a left ventricular assist
device. The previously reviewed trials on the use of ICDs
as a bridge to transplant (population 13) generally were
equally distributed between patients with ischemic car-
diomyopathy and NICM and have not shown a difference
in the beneﬁt of ICD based on etiology of cardiomyop-
athy. In one single-center study of 61 patients who
received LVADs, sustained ventricular arrhythmias
occurred in 43% of patients and were more likely to be
observed in patients with NICM (approximately 60%)
(118). The LVAD can be used as a bridge to recovery in
some patients with NICM. In IMAC-2, an LVAD was used
in 14 patients (3.8%), and in 8 patients the LVAD was usedas a bridge to recovery (119). In this group of patients,
LVEF improved from 0.20 at baseline to 0.49 at the
6-month follow-up.
The ACC/AHA/HRS 2008 Guidelines on Device-Based
Therapy give a Class IIa recommendation for ICD
implantation in nonhospitalized patients awaiting trans-
plantation (5). Given the results of the retrospective
studies and the subanalysis of IMAC-2, ICD therapy can be
useful for patients who have had recently identiﬁed NICM
(<9 months) who have been listed for transplant or who
have undergone LVAD implantation and will be dis-
charged from the hospital.
8. DUAL-CHAMBER VS SINGLE-CHAMBER
ICD RECOMMENDATIONS
Recommendations:
 In patients with symptomatic sinus node dysfunction,
an atrial lead is recommended.
 In patients with sinus bradycardia and/or AV conduction
disturbances limiting the use and/or up-titration of
necessary beta-blocker or other negative chronotropic
drug therapy, an atrial lead is recommended.
 In patients with sinus rhythm who have a documented
second- or third-degree AV block, but who are not
otherwise candidates for cardiac resynchronization
therapy, an atrial lead is recommended.
 In patients with bradycardia-induced or pause-
dependent ventricular tachyarrhythmia (such as
patients with long QT syndrome and torsades de
pointes) an atrial lead can be useful.
 In patients with a documented history of atrial
arrhythmias (but not in permanent atrial ﬁbrillation),
an atrial lead may be considered.
 In patients with hypertrophic cardiomyopathy and a
signiﬁcant resting or provocable left ventricular out-
ﬂow tract gradient, an atrial lead may be considered.
 In patients with no documented history of atrial
arrhythmias who have no other reason for requiring an
atrial lead, an atrial lead is not recommended.
 In patients with permanent or longstanding persistent
atrial ﬁbrillation in whom efforts to restore or maintain
sinus rhythm are not planned, an atrial lead is not
recommended.
 In patients with conditions likely to result in VF
(rather than monomorphic or polymorphic VT) with-
out a bradycardia-induced or pause-dependent mech-
anism of initiation and no other indication for an
atrial lead, an atrial lead is not recommended.
VF is the arrhythmia anticipated in conditions such as
idiopathic ventricular ﬁbrillation, Brugada syndrome,
catecholaminergic polymorphous ventricular tachycardia,
and short QT syndrome.
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1167For every patient receiving an ICD in whom cardiac
resynchronization therapy is either not indicated or not
desired, physicians must choose to implant either a
single-chamber ICD or a dual-chamber ICD. The pub-
lished scientiﬁc evidence addressing this speciﬁc ques-
tion, however, is limited. Current clinical guideline
documents do not provide speciﬁc recommendations as
to how physicians should proceed. Whereas the ACC/
AHA/NASPE 2002 Guideline Update for Implantation of
Pacemakers and Antiarrhythmia Devices stated that a
“dual-chamber pacemaker-ventricular deﬁbrillator
device is an appropriate choice for an ICD candidate who
has a concomitant need for dual-chamber pacing or a
patient with supraventricular tachycardia thought likely
to lead to inappropriate ICD therapies,” all reference to
selection of single-chamber or dual-chamber ICDs was
removed from the ACC/AHA/HRS 2008 Guidelines for
Device-Based Therapy of Cardiac Rhythm Abnormalities
(5,120). Given the limited evidence and lack of pro-
fessional society guideline recommendations, wide var-
iation in practice has emerged, ranging from some
centers implanting no dual-chamber ICDs and some
centers choosing to implant only dual-chamber ICDs
(121). The next section reviews the scientiﬁc evidence
underlying the current recommendations in this docu-
ment regarding implantation of an atrial lead in patients
receiving an ICD.
8.1 Randomized Trial Evidence from the Major Efﬁcacy Trials of
ICD Therapy
The vast majority of the nearly 5000 patients enrolled in
the trials that established the efﬁcacy of ICDs for the
secondary prevention and primary prevention of sudden
cardiac death received single-chamber ICDs (1,3). A
notable exception, however, was the MADIT-II trial, in
which nearly 44% of patients (313/717) received dual-
chamber devices by physician choice (2). It is important to
note that among patients randomly assigned to receive an
ICD, selection of a single- or dual-chamber device was not
randomized. In a subsequent substudy of MADIT-II,
patients receiving dual-chamber devices had wider QRS
complexes by electrocardiography, greater burden of
comorbidity, and were older than the patients who
received single-chamber devices (122). There were no
signiﬁcant differences in heart failure hospitalization,
mortality, or risk of inappropriate shocks between those
who received single- or dual-chamber ICDs.
8.2 Beneﬁts of Dual-Chamber ICDs
The addition of an atrial lead to an ICD system provides
several potential beneﬁts. Dual-chamber devices can
provide atrial pacing to patients with sinus node dys-
function or in the setting of other needs for atrial and/or
dual-chamber pacing. In a recent analysis of the NCDRICD database, less than 5% of ICD implants were placed
for patients with a second- or third-degree AV block, and
12% were placed for bradycardic arrest (123). Pacing can be
useful, for example, in selected patients with hyper-
trophic cardiomyopathy, myotonic dystrophy, cardiac
sarcoidosis, inﬁltrative cardiomyopathies, and long QT
syndrome. In particular, atrial or dual-chamber pacing
receives a Class I recommendation for patients with long
QT syndrome in the recently published consensus docu-
ment on pacemaker mode selection (87). Initial placement
of an atrial lead will reduce the likelihood and associated
morbidity of a future upgrade procedure if sinus node
dysfunction develops. The addition of an atrial lead
allows for the use of dual-chamber arrhythmia discrim-
ination algorithms and clearer clinical interpretation of
device electrograms to differentiate ventricular and
supraventricular arrhythmias, including the clear dem-
onstration of ventriculoatrial dissociation during sus-
tained monomorphic VT. Distinguishing monomorphic VT
from supraventricular tachycardia presents challenges for
clinicians caring for patients with ICDs. Rigorous studies,
however, have had mixed results, demonstrating an
improvement in arrhythmia discrimination and/or
reduction in inappropriate therapies in some but not all
studies (124–128). Placement of an atrial lead at the time
of ICD implantation can also obviate the need for upgrade
to a dual-chamber system in the future, should a need for
atrial pacing arise. Goldberger and colleagues (129) found
using a decision analysis model that the strategy of dual-
chamber ICD selection in most patients made most sense,
but this study assumed no increased risk with the addi-
tion of an atrial lead. In addition, the authors did not take
into account the increased potential for lead failure and/
or recall, and they also did not fully consider the shorter
battery life of dual-chamber pulse generators. No
randomized trial has clearly demonstrated a superiority of
dual-chamber devices in terms of risk of inappropriate
shocks, hospitalizations, or mortality.
8.3 Potential Risks of Dual-Chamber Device Selection
The addition of an atrial lead to an ICD system also poses
several potential risks. Additional leads are associated
with increased risk of dislodgement and other complica-
tions, including an increased risk of periprocedural mor-
tality in dual-chamber ICD recipients compared with
those who receive single-chamber devices (130,131). Bat-
tery life tends to be somewhat shorter in dual-chamber
devices, which might lead to a greater need for generator
replacement over patients’ lifetimes. Additional leads can
also present a theoretical risk of lead failure and/or recall,
and in the event of infection or other factors that require
lead extraction, additional leads present an incremental
risk of vascular complications. Dual-chamber devices are
also more expensive, because of both the additional lead
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hand, upgrade procedures from single-chamber devices
to dual-chamber devices incur both increased ﬁnancial
costs and the procedural risks to the patient that could be
mitigated by implantation of a dual-chamber device as an
upfront strategy (86).
Dual-chamber devices can also induce harm if strat-
egies to minimize right ventricular pacing are not used. In
the Dual-chamber and VVI Implantable Deﬁbrillator
(DAVID) trial, patients with decreased left ventricular
systolic function and indications for ICD therapy received
dual-chamber devices but were then randomly assigned
to either VVI (single-chamber) or DDDR (dual-chamber
with rate adaption) bradycardia pacing programming
(132); in this trial, there was increased risk of the com-
posite outcome of heart failure hospitalization plus mor-
tality in the dual-chamber pacing arm, primarily in
association with the greater proportion of right ven-
tricular pacing with DDDR programming. In a subsequent
subanalysis of DAVID, even patients with “soft indica-
tions” for pacing such as sinus bradycardia or ﬁrst-degree
AV block had poorer outcomes with the DDDR pacing
(133). These risks of increased mortality and heart failure
can be mitigated, however, with strategies to minimize or
eliminate right ventricular pacing (134,135).
Even with the understanding that direct visualization
of atrial electrograms can help clinicians to better dis-
tinguish sustained monomorphic VT in the care of indi-
vidual patients, the increased risk of periprocedural
complications and lack of clear beneﬁt in rigorous studies
in terms of hard clinical outcomes (such as incident
inappropriate shocks, hospitalizations, or mortality) bring
into question the practice of routine implantation of an
atrial lead for the intended goal of improving discrim-
ination of supraventricular arrhythmias from mono-
morphic VT, particularly in the era of modern
programming strategies that have dramatically reduced
the incidence of inappropriate therapies (133–136). In
conditions where VF or polymorphic VT (rather than
monomorphic VT) is the anticipated arrhythmia (such as
idiopathic ventricular ﬁbrillation, Brugada syndrome,
short QT syndrome, and catecholaminergic polymorphic
ventricular tachycardia), the value of an atrial lead would
be even smaller.
8.4 Real-World Practice Patterns with Regard to Selection of
Single-Chamber and Dual-Chamber ICDs
Although the majority of patients in the randomized trials
of ICD therapy received single-chamber devices, and
there is no randomized trial evidence demonstrating a
superiority of the strategy of dual-chamber device selec-
tion, the majority of patients undergoing implantation of
an ICD in the United States receive a dual-chamber
device. After excluding those receiving cardiacresynchronization therapy devices, nearly two-thirds of
all patients undergoing ICD implantation in the NCDR ICD
Registry receive dual-chamber devices, and fewer than
half of those receiving dual-chamber devices had clear
bradycardia indications for dual-chamber pacing (123). In
subsequent analyses excluding those patients with bra-
dycardia indications for pacing, the preponderance of
dual-chamber device selection persisted, but there was
wide variation in practice patterns; some physicians and
centers implanted no dual-chamber devices at all, and
some implanted dual-chamber devices in all patients
(121). This variation in practice strongly suggests a lack of
consensus among practicing electrophysiologists regard-
ing the best strategy for ICD device selection.
8.5 Device Selection in the Era of
Modern Programming Strategies
Conventional ICD programming strategies have demon-
strated incident appropriate therapies in more than 15%
(MADIT-II) of cases, and incident inappropriate therapies
in 10%–18% of cases in the ﬁrst year after ICD implanta-
tion. However, modern programming strategies can dra-
matically reduce the incidence of both appropriate and
inappropriate therapies. These strategies include mini-
mization of right ventricular pacing, increased time from
the onset of tachycardia until detection criteria are met,
higher heart rate criteria than were conventionally
employed to achieve arrhythmia detection, and more
aggressive use of antitachycardia pacing (137–140). These
strategies reduce the incidence of shocks, appropriate and
inappropriate therapies, and, in the case of the Multi-
center Automatic Deﬁbrillator Implantation Trial: Reduce
Inappropriate Therapy (MADIT-RIT), such strategies can
also reduce mortality (137,138).
In MADIT-RIT, recipients of primary prevention ICDs
were randomly assigned to either conventional ICD pro-
gramming or to one of two strategies that employed
modern programming techniques (137). The incidence of
inappropriate therapies was 18% in the ﬁrst year in the
“conventional” arm, but with newer strategies, 5% or less
received inappropriate therapies in the ﬁrst year after
device implantation.
These studies evaluating modern programming strat-
egies are relevant to the decision to implant an atrial lead
in patients undergoing implantation of an ICD for two
important reasons. First, although all the patients in
MADIT-RIT did have an atrial lead (as part of either a
dual-chamber device or a cardiac resynchronization
therapy deﬁbrillator) to ensure deﬁnitive arrhythmia
adjudication for study purposes, the programming strat-
egies evaluated in the study can be equally employed in
the absence of an atrial lead. Furthermore, with the dra-
matic reduction in the incidence of inappropriate thera-
pies resulting from the use of these newer programming
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enhanced arrhythmia discrimination might be reduced.
Indeed, a preliminary report of the Use of Dual-chamber
ICD With Special Programmed Features to Lower the Risk
of Inappropriate Shock (RAPTURE) study found that in
100 patients randomized to either single-chamber or dual-
chamber ICDs, the incidence of inappropriate therapies
was 2% at 1 year for both groups (140).
9. DOCUMENTATION OF CLINICAL DECISIONS
In appropriately selected patients, ICD implantation is an
important component for providing the best health care
and improving survival. In both the MADIT-II and SCD-
HeFT, the absolute mortality beneﬁt after 3 years is 6%–
9% (1,2). To put these data into perspective, chronic beta-
blocker therapy after MI was associated with an absolute
2.5%–3.5% reduction in 3-year mortality in the Carvedilol
Post-Infarct Survival Control in Left Ventricular Dys-
function (CAPRICORN) study and the Beta Blocker Heart
Attack Trial (BHAT) (141,142). However, ICD therapy is
expensive, and it is critical to choose patients who will
beneﬁt from implantation.
Documentation of the reasons for ICD implantation are
essential for all patients, but even more critical for those
patients who have not been represented in clinical trials
because the potential survival beneﬁt must be calculated
by taking the additional risks of comorbid conditions into
account. For example, for the patient in whom an ICD is
being implanted within the 40-day window after myo-
cardial infarction because of high-grade AV block and
requirement for permanent pacing, it is essential for the
clinician to document the clinical reasons behind the
decision, particularly because two trials have demon-
strated higher nonarrhythmia-related mortality asso-
ciated with ICD placement during this time period (13,14).
As suggested in the recommendations from this con-
sensus statement, the clinician should document the
urgent and nonelective requirement for ventricular rate
support. In addition, once a decision to implant an ICD
has been made, the clinician should also document the
reasons for the pacing system that is implanted—single-
chamber ICD, dual-chamber ICD, or an ICD with cardiac
resynchronization capabilities. This decision must be
made on the basis of previously published documents, the
ACC/AHA/HRS 2008 Guidelines on Device-Based Therapy,
the 2012 ACC/AHA/HRS Focused Update of this document,
and the 2012 HRS/ACC Expert Consensus Statement
on Pacemaker Device and Mode Selection (5,8,87). No
clinical document can account for all possibilities. For
example, selected patients with hypertrophic cardiomy-
opathy might beneﬁt from ICD implantation, and ICD
implantation within 90 days of revascularization might be
appropriate in a patient with both hypertrophiccardiomyopathy and coronary artery disease (143). Again,
the clinician should document the reasoning for ICD
implantation.
The important and subtle distinctions of doc-
umentation must be understood by both health care
providers and coding specialists. In a discussion of a
hospital response to a United States Department of Jus-
tice audit, in an initial analysis of data from a single
academic medical center, approximately 30% of patients
were identiﬁed as possible inappropriate ICD recipients
due to MI within the prior 40 days. However, on sub-
sequent review of the medical record, the clinician
responsible for the care of the patient and an independ-
ent reviewer both felt the abnormal troponin levels did
not represent a myocardial infarction in 20% of the cases
(144). In response to this ﬁnding, the coders at the
institution received focused education and training on
the clinical documentation, and a “same-day” peer
review by all practicing electrophysiologists was insti-
tuted. In addition to these changes, the hospital insti-
tuted a routine quality assurance process that uses
nursing staff evaluation of the medical record of patients
who receive ICD implants. Peer review of patients
undergoing ICD implantation is an important component
of any quality improvement process. Good doc-
umentation is probably the best protection a clinician has
against being cited for inappropriate ICD implantation
and legal liability.
10. FUTURE RESEARCH AND DIRECTIONS
Clinicians should continue to support registries such as
the NCDR for analysis of ICD implantation. The ICD
component of the NCDR was implemented in 2005, and in
the most recent published report, records from 850,000
ICD implants performed from registry inception to the
end of 2011 were available for analysis (145). In a recent
analysis of the NCDR ICD Registry, 22.5% of patients
received a nonevidence–based ICD implantation, many
identiﬁed by clinical situations addressed in this docu-
ment: 8.3% of patients received an ICD within 40 days of
an MI, 0.7% within 3 months of a CABG, and 14.0% within
3 months of an initial heart failure diagnosis (146).
Another analysis of the ICD registry found that the mag-
nitude of survival beneﬁts described in randomized con-
trolled trials was similar to the survival beneﬁts in a
comparable patient group from the NCDR (147). In its
latest iteration, the NCDR-ICD Registry has been collect-
ing data on ICD replacements and lead longevity.
Although the accuracy of some components of the registry
data has been questioned, the ﬁnal solution must be for
hospitals and health care providers to make accurate
documentation and data input a high priority. Although
the NCDR is publicly funded, industry and other groups
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tional registries can provide “cross-checking” of the
NCDR, and those registries that are maintained by
industry must be made as transparent as possible with
scientiﬁc access.
Part of improving registry data as the United States
continues to slowly evolve to a fully electronic health
record is the standardization of deﬁnitions for key data
elements. Recently, the 2013 ACC/AHA Key Data Ele-
ments and Deﬁnition for Measuring the Clinical Man-
agement and Outcomes of Patients with Acute Coronary
Syndromes and Coronary Artery Disease has been pub-
lished (148). This document will help improve con-
sistency and overall quality among hospitals and health
care providers. Initiatives that standardize data elements
and deﬁne best practice relating to ICD therapy will be
critical for leveraging the beneﬁts of ICD therapy to large
populations.
Although recent medical literature and popular press
have focused on inappropriate use of ICDs, it is also
important to acknowledge that there are patients who
would beneﬁt from ICD therapy who do not receive
counseling on the potential beneﬁts of this therapy.
Castellanos et al. (149) mailed a survey about the ICD
guidelines to 3,000 physicians, composed of equal
numbers of family practice physicians, internists, and
general cardiologists selected randomly from the Ameri-
can Medical Association Masterﬁle. Answers discordant
with the current guidelines were extremely common. In
fact, almost 30% of respondents, including 7% of car-
diologists, would never refer patients for consideration
of a primary prevention ICD. In another analysis, inves-
tigators examined the Improve the Use of Evidence Based
Heart Failure Therapies in the Outpatient Setting
(IMPROVE HF) database, and found that of 7,221 patients
who met Class I criteria for ICD patients (after excluding
4% of patients who had documented contraindications),
3659 patients (50.7%) received ICDs (150). In addition,
when examining individual practices, the use of ICDs in
eligible patients ranged from 0%–100%, with the 10th
and 90th percentiles 27.3% and 74.6%, respectively.
Subsequent analysis of the IMPROVE database after the
institution of quality improvement measures demon-
strated a signiﬁcant increase in guideline adherence
(absolute improvement of 18%) from baseline to 24
months (151).
Future research should continue to evaluate the
effectiveness and value of ICD therapy. For determining
value, lifetime costs and beneﬁts must be calculated.
Although the ﬁrst iteration of the NCDR focused on
immediate postprocedural complications, the most recent
version of the registry incorporates longitudinal follow-
up. This transition is important because ICD therapy must
be evaluated in its entirety. Complications with devicereplacements and appropriate and individualized pro-
gramming of ICDs have important effects on the overall
costs. Another important downstream complication is
lead fracture or device malfunction. Over the past decade,
there have been several highly publicized recalls of ICD
generators and leads. Historically, the annual failure rate
for ICD leads has been <1% per year, but two smaller-
caliber leads—the Medtronic Sprint Fidelis and the St.
Jude Riata leads—have higher annual failure rates,
approaching 5% per year (152). When evaluating the value
of ICD therapy, both additional costs and beneﬁts must be
taken into account.
Finally, it is critical that there is consistency among
the various documents that clinicians use to guide
therapy choices and that guide reimbursement. As
mentioned earlier, there are several guideline docu-
ments that provide basic recommendations for ICD use
that are based on strong evidence from randomized
clinical trials. Documents such as this consensus state-
ment and the 2013 Appropriate Use Criteria for ICDs
attempt to assist the physician in caring for a patient
with unique clinical characteristics (9). As addressed in
this document, differences in interpretation of the clin-
ical data can lead to different recommendations, which
might be unavoidable given the complexities of clinical
medicine and differences in the interpretation of data.
However, it is critical for the writing committees of these
documents to carefully assess the consistency of new
documents and acknowledge and discuss differences.
Reimbursement tables for medical care, such as National
Coverage Determination statements produced by the
United States Federal Government, are often not upda-
ted as frequently as clinical documents. For example, the
National Coverage Determination for ICD therapy was
last updated in 2005. Since this publication, there have
been three Guidelines, two Focused Updates of pre-
viously published Guidelines, one Appropriate Use
Document, and now two consensus statements relevant
to ICD implantation that would be applicable to patients
in the United States.
Since its inception more than 40 years ago, the ICD has
evolved to a widely accepted and important treatment for
patients with cardiovascular disease who are at risk of
life-threatening ventricular arrhythmias. As with any
complex and expensive treatment, we must continue to
reﬁne our understanding of who beneﬁts from ICD
implantation and how to optimally implement ICD ther-
apy in these patients.APPENDIX A
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